Constitutive	O
expression	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
melanoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
results	O
from	O
the	O
transcription	O
of	O
class	B-DNA
II	I-DNA
transactivator	I-DNA
abnormally	O
initiated	O
from	O
its	O
B	B-DNA
cell-specific	I-DNA
promoter	I-DNA
.	O

In	O
melanoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
two	O
different	O
patterns	O
of	O
MHC	O
class	O
II	O
expression	O
have	O
been	O
described	O
,	O
either	O
an	O
IFN	O
gamma-inducible	O
expression	O
of	O
HLA-DR	B-DNA
and	O
HLA-DP	B-DNA
,	O
with	O
a	O
faint	O
or	O
null	O
expression	O
of	O
HLA-DQ	B-DNA
,	O
resembling	O
that	O
described	O
for	O
melanocytes	B-cell_type
,	O
or	O
a	O
constitutive	O
expression	O
,	O
i.e.	O
,	O
IFN-gamma	O
independent	O
,	O
of	O
all	O
three	O
HLA-D	B-DNA
isotypes	I-DNA
.	O

As	O
this	O
latter	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
more	O
rapid	O
progression	O
of	O
melanoma	O
tumors	O
,	O
we	O
have	O
analyzed	O
in	O
different	O
melanoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
the	O
molecular	O
mechanisms	O
leading	O
to	O
this	O
abnormal	O
pattern	O
of	O
MHC	O
class	O
II	O
expression	O
.	O

In	O
agreement	O
with	O
the	O
evidence	O
of	O
a	O
coordinate	O
transcription	O
of	O
the	O
HLA-D	B-DNA
genes	I-DNA
in	O
these	O
cell	O
lines	O
,	O
we	O
have	O
shown	O
the	O
constitutive	O
expression	O
of	O
CIITA	B-RNA
(	I-RNA
class	I-RNA
II	I-RNA
transactivator	I-RNA
)	I-RNA
transcripts	I-RNA
,	O
CIITA	B-protein
being	O
known	O
as	O
the	O
master	O
switch	O
of	O
MHC	O
class	O
II	O
expression	O
.	O

Unexpectedly	O
,	O
these	O
transcripts	O
initiate	O
from	O
promoter	B-DNA
III	I-DNA
of	O
the	O
CIITA	B-DNA
gene	I-DNA
,	O
a	O
promoter	O
that	O
is	O
mainly	O
used	O
constitutively	O
in	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

This	O
expression	O
was	O
further	O
shown	O
to	O
occur	O
through	O
factor	O
(	O
s	O
)	O
acting	O
on	O
the	O
enhancer	O
located	O
upstream	O
of	O
CIITA	B-DNA
promoter	I-DNA
III	I-DNA
,	O
which	O
was	O
previously	O
described	O
in	O
epithelioid	B-cell_type
cells	I-cell_type
as	O
an	O
IFN-gamma-response	O
sequence	O
.	O

The	O
hypothesis	O
of	O
a	O
general	O
abnormality	O
of	O
the	O
IFN-gamma	O
transduction	O
pathway	O
was	O
dismissed	O
.	O

Constitutive	O
transcription	O
of	O
CIITA	B-DNA
from	O
promoter	B-DNA
III	I-DNA
having	O
been	O
observed	O
in	O
unrelated	O
melanoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
we	O
propose	O
the	O
hypothesis	O
that	O
this	O
phenomenon	O
might	O
not	O
be	O
a	O
random	O
event	O
,	O
but	O
could	O
be	O
linked	O
to	O
the	O
neoplasic	O
state	O
of	O
the	O
melanoma	B-cell_type
cells	I-cell_type

Flexible	NULL
,	NULL
Intuitive	NULL
,	NULL
and	NULL
Luminex	NULL
.	NULL

C4	NULL
-	NULL
«	NULL
gf\	NULL
_	NULL
}	NULL
Affordable	NULL
Cytometry	NULL
,	NULL
warmmore	NULL
complexity	NULL
simplified	NULL
.	NULL

Guava®	NULL
easyCyte	NULL
``	NULL
Flow	NULL
Cytometers	NULL
.	NULL

#	NULL
s	NULL
mJournal	NULL
of	NULL
Constitutive	NULL
Expression	NULL
of	NULL
MHC	NULL
Class	NULL
II	NULL
P	NULL
Itmnmunolo	NULL
gy	NULL
Genes	NULL
in	NULL
Melanoma	NULL
Cell	NULL
Lines	NULL
Results	NULL
from	NULL
the	NULL
Transcription	NULL
of	NULL
Class	NULL
II	NULL
Transactivator	NULL
Abnormally	NULL
Initiated	NULL
from	NULL
Its	NULL
B	NULL
Cell-Specific	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
Promoter	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Virginie	NULL
Deffrennes	NULL
,	NULL
Jocelyn	NULL
Vedrenne	NULL
,	NULL
Marie-Claude	NULL
Stolzenberg	NULL
,	NULL
Janet	NULL
Piskurich	NULL
,	NULL
Giovanna	NULL
Barbieri	NULL
,	NULL
Jenny	NULL
P.	NULL
Ting	NULL
,	NULL
Dominique	NULL
Charron	NULL
and	NULL
Catherine	NULL
Alcaide-Loridan	NULL
J	NULL
Immunol	NULL
2001	NULL
;	NULL
167:98-106	NULL
;	NULL
;	NULL
doi	NULL
:	NULL
10.4049/jimmunol.167.1.98	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/167/1/98	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
54	NULL
articles	NULL
,	NULL
21	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/167/1/98.full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
Constitutive	NULL
Expression	NULL
of	NULL
MHC	NULL
Class	NULL
II	NULL
Genes	NULL
in	NULL
Melanoma	NULL
Cell	NULL
Lines	NULL
Results	NULL
from	NULL
the	NULL
Transcription	NULL
of	NULL
Class	NULL
II	NULL
Transactivator	NULL
Abnormally	NULL
Initiated	NULL
from	NULL
Its	NULL
B	NULL
Cell-Specific	NULL
Promoter	NULL
'	NULL
Virginie	NULL
Deffrennes	NULL
,	NULL
*	NULL
Jocelyn	NULL
Vedrenne	NULL
,	NULL
*	NULL
Marie-Claude	NULL
Stolzenberg	NULL
,	NULL
``	NULL
Janet	NULL
Piskurich	NULL
,	NULL
*	NULL
Giovanna	NULL
Barbieri	NULL
,	NULL
**	NULL
Jenny	NULL
P.	NULL
Ting	NULL
,	NULL
``	NULL
Dominique	NULL
Charron	NULL
,	NULL
*	NULL
and	NULL
Catherine	NULL
Alcaide-Loridan**	NULL
In	NULL
melanoma	NULL
cell	NULL
lines	NULL
,	NULL
two	NULL
different	NULL
patterns	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
have	NULL
been	NULL
described	NULL
,	NULL
either	NULL
an	NULL
IFN	NULL
y-inducible	NULL
expression	NULL
of	NULL
HLA-DR	NULL
and	NULL
HLA-DP	NULL
,	NULL
with	NULL
a	NULL
faint	NULL
or	NULL
null	NULL
expression	NULL
of	NULL
HLA-DQ	NULL
,	NULL
resembling	NULL
that	NULL
described	NULL
for	NULL
melanocytes	NULL
,	NULL
or	NULL
a	NULL
constitutive	NULL
expression	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
IFN-y	NULL
independent	NULL
,	NULL
of	NULL
all	NULL
three	NULL
HLA-D	NULL
isotypes	NULL
.	NULL

As	NULL
this	NULL
latter	NULL
phenotype	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
a	NULL
more	NULL
rapid	NULL
progression	NULL
of	NULL
melanoma	NULL
tumors	NULL
,	NULL
we	NULL
have	NULL
analyzed	NULL
in	NULL
different	NULL
melanoma	NULL
cell	NULL
lines	NULL
the	NULL
molecular	NULL
mechanisms	NULL
leading	NULL
to	NULL
this	NULL
abnormal	NULL
pattern	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
the	NULL
evidence	NULL
of	NULL
a	NULL
coordinate	NULL
transcription	NULL
of	NULL
the	NULL
HLA-D	NULL
genes	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
CITA	NULL
(	NULL
class	NULL
II	NULL
transactivator	NULL
)	NULL
transcripts	NULL
,	NULL
CIITA	NULL
being	NULL
known	NULL
as	NULL
the	NULL
master	NULL
switch	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
.	NULL

Unexpectedly	NULL
,	NULL
these	NULL
transcripts	NULL
initiate	NULL
from	NULL
promoter	NULL
III	NULL
of	NULL
the	NULL
CHTA	NULL
gene	NULL
,	NULL
a	NULL
promoter	NULL
that	NULL
is	NULL
mainly	NULL
used	NULL
constitutively	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

This	NULL
expression	NULL
was	NULL
further	NULL
shown	NULL
to	NULL
occur	NULL
through	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
acting	NULL
on	NULL
the	NULL
enhancer	NULL
located	NULL
upstream	NULL
of	NULL
CITA	NULL
promoter	NULL
III	NULL
,	NULL
which	NULL
was	NULL
previously	NULL
described	NULL
in	NULL
epithelioid	NULL
cells	NULL
as	NULL
an	NULL
IFN-y-response	NULL
sequence	NULL
.	NULL

The	NULL
hypothesis	NULL
of	NULL
a	NULL
general	NULL
abnormality	NULL
of	NULL
the	NULL
IFN-y	NULL
transduction	NULL
pathway	NULL
was	NULL
dismissed	NULL
.	NULL

Constitutive	NULL
transcription	NULL
of	NULL
CIZTA	NULL
from	NULL
promoter	NULL
III	NULL
having	NULL
been	NULL
observed	NULL
in	NULL
unrelated	NULL
melanoma	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
propose	NULL
the	NULL
hypothesis	NULL
that	NULL
this	NULL
phenomenon	NULL
might	NULL
not	NULL
be	NULL
a	NULL
random	NULL
event	NULL
,	NULL
but	NULL
could	NULL
be	NULL
linked	NULL
to	NULL
the	NULL
neoplasic	NULL
state	NULL
of	NULL
the	NULL
melanoma	NULL
cells	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
2001	NULL
,	NULL
167	NULL
:	NULL
98-106.	NULL
elanoma	NULL
arise	NULL
from	NULL
melanocytes	NULL
that	NULL
are	NULL
pigment-M	NULL
producing	NULL
cells	NULL
derived	NULL
from	NULL
the	NULL
neural	NULL
crest	NULL
,	NULL
and	NULL
represent	NULL
the	NULL
most	NULL
lethal	NULL
type	NULL
of	NULL
cutaneous	NULL
cancers	NULL
.	NULL

As	NULL
chemotherapy	NULL
is	NULL
poorly	NULL
efficient	NULL
on	NULL
this	NULL
type	NULL
of	NULL
cancers	NULL
(	NULL
1	NULL
)	NULL
,	NULL
mainly	NULL
on	NULL
distant	NULL
metastasis	NULL
,	NULL
immunotherapy	NULL
has	NULL
been	NULL
consid-ered	NULL
.	NULL

With	NULL
the	NULL
evidence	NULL
of	NULL
specific	NULL
tumor	NULL
Ags	NULL
presented	NULL
by	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

2	NULL
)	NULL
,	NULL
vaccination	NULL
of	NULL
patients	NULL
with	NULL
tumoral	NULL
peptides	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
was	NULL
undertaken	NULL
.	NULL

This	NULL
was	NULL
demonstrated	NULL
to	NULL
be	NULL
efficient	NULL
,	NULL
even	NULL
though	NULL
moderated	NULL
by	NULL
results	NULL
showing	NULL
that	NULL
these	NULL
treatments	NULL
might	NULL
induce	NULL
immune	NULL
escape	NULL
of	NULL
the	NULL
tumors	NULL
through	NULL
MHC	NULL
class	NULL
I	NULL
loss	NULL
of	NULL
expression	NULL
(	NULL
5	NULL
)	NULL
or	NULL
mutations	NULL
in	NULL
the	NULL
vaccinated	NULL
tumor	NULL
Ag	NULL
(	NULL
4	NULL
)	NULL
.	NULL

*Unité	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
,	NULL
Unité	NULL
396	NULL
,	NULL
Centre	NULL
de	NULL
Recherches	NULL
Biomédicales	NULL
des	NULL
Cordeliers	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
;	NULL
*Unité	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
,	NULL
Unité	NULL
429	NULL
,	NULL
Hopital	NULL
Necker	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
;	NULL
*Department	NULL
of	NULL
Basic	NULL
Sciences	NULL
,	NULL
Mercer	NULL
University	NULL
Medical	NULL
School	NULL
,	NULL
Macon	NULL
,	NULL
GA	NULL
31207	NULL
;	NULL
and	NULL
Lineberger	NULL
Comprehensive	NULL
Cancer	NULL
Center	NULL
,	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
NC	NULL
27599	NULL
Received	NULL
for	NULL
publication	NULL
October	NULL
31	NULL
,	NULL
2000	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
April	NULL
18	NULL
,	NULL
2001	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Fondation	NULL
pour	NULL
la	NULL
Recherche	NULL
Médicale	NULL
,	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
(	NULL
Progrés	NULL
)	NULL
,	NULL
and	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
.	NULL

V.D	NULL
.	NULL

was	NULL
the	NULL
recipient	NULL
of	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
,	NULL
and	NULL
J.V	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
the	NULL
Ligue	NULL
Nationale	NULL
contre	NULL
le	NULL
Cancer	NULL
et	NULL
la	NULL
Fondation	NULL
pour	NULL
la	NULL
Recherche	NULL
Médicale	NULL
.	NULL

*	NULL
Current	NULL
address	NULL
:	NULL
Istituto	NULL
di	NULL
Biologia	NULL
dello	NULL
Svillupo	NULL
,	NULL
Consiglio	NULL
Nazionale	NULL
delle	NULL
Ricerche	NULL
(	NULL
CNR	NULL
)	NULL
,	NULL
152	NULL
via	NULL
Ugo	NULL
La	NULL
Malfa	NULL
,	NULL
Palermo	NULL
,	NULL
Italy	NULL
.	NULL

3	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Catherine	NULL
Alcaide-Loridan	NULL
.	NULL

Unité	NULL
d'Immunogénétique	NULL
Humaine	NULL
,	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
,	NULL
Unité	NULL
396	NULL
,	NULL
Centre	NULL
de	NULL
Recherches	NULL
Biomédicales	NULL
des	NULL
Cordeliers	NULL
,	NULL
15	NULL
rue	NULL
de	NULL
I'Ecole	NULL
de	NULL
Médecine	NULL
,	NULL
75270	NULL
Paris	NULL
cedex	NULL
06	NULL
,	NULL
France	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
Catherine	NULL
.	NULL

Alcaide	NULL
@	NULL
bhdc.jussicu.fr	NULL
Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
More	NULL
recently	NULL
,	NULL
attention	NULL
has	NULL
focused	NULL
on	NULL
the	NULL
role	NULL
of	NULL
CD4	NULL
*	NULL
lymphocytes	NULL
in	NULL
tumor	NULL
elimination	NULL
(	NULL
see	NULL
Ref	NULL
.	NULL

6	NULL
for	NULL
a	NULL
review	NULL
)	NULL
with	NULL
the	NULL
evidence	NULL
of	NULL
tumor	NULL
Ag-specific	NULL
CD4	NULL
*	NULL
lymphocytes	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

However	NULL
,	NULL
even	NULL
though	NULL
both	NULL
CD4	NULL
*	NULL
and	NULL
CD8	NULL
*	NULL
cells	NULL
infiltrate	NULL
the	NULL
melanoma	NULL
tumors	NULL
(	NULL
9	NULL
)	NULL
,	NULL
these	NULL
cancer	NULL
cells	NULL
often	NULL
acquire	NULL
the	NULL
capacity	NULL
to	NULL
escape	NULL
immune	NULL
surveillance	NULL
through	NULL
lymphocyte	NULL
anergy	NULL
via	NULL
mechanisms	NULL
that	NULL
are	NULL
not	NULL
yet	NULL
unraveled	NULL
(	NULL
10	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
melanoma	NULL
cells	NULL
often	NULL
display	NULL
a	NULL
constitutive	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
,	NULL
which	NULL
is	NULL
usually	NULL
restricted	NULL
to	NULL
professional	NULL
APC	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Although	NULL
MHC	NULL
class	NULL
II	NULL
presentation	NULL
of	NULL
tumor	NULL
Ags	NULL
by	NULL
melanoma	NULL
cells	NULL
has	NULL
been	NULL
described	NULL
(	NULL
14	NULL
)	NULL
,	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
associated	NULL
with	NULL
a	NULL
better	NULL
progression	NULL
of	NULL
primary	NULL
melanoma	NULL
and	NULL
a	NULL
higher	NULL
metastatic	NULL
dissemination	NULL
(	NULL
15	NULL
)	NULL
.	NULL

MHC	NULL
class	NULL
II	NULL
constitutive	NULL
expression	NULL
in	NULL
melanomas	NULL
is	NULL
considered	NULL
nowadays	NULL
as	NULL
a	NULL
progression	NULL
marker	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
was	NULL
proposed	NULL
that	NULL
MHC	NULL
class	NULL
II-expressing	NULL
tumors	NULL
might	NULL
mimic	NULL
an	NULL
APC	NULL
and	NULL
induce	NULL
lymphocyte	NULL
anergy	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
accessory	NULL
signals	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Within	NULL
the	NULL
hypothesis	NULL
of	NULL
a	NULL
role	NULL
in	NULL
the	NULL
immune	NULL
escape	NULL
and	NULL
tolerance	NULL
induction	NULL
,	NULL
mechanisms	NULL
leading	NULL
to	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
Ags	NULL
in	NULL
melanoma	NULL
cells	NULL
must	NULL
be	NULL
investigated	NULL
.	NULL

MHC	NULL
class	NULL
II	NULL
molecules	NULL
are	NULL
represented	NULL
by	NULL
three	NULL
isotypes	NULL
,	NULL
HLA-DR	NULL
,	NULL
HLA-DQ	NULL
,	NULL
and	NULL
HLA-DP	NULL
,	NULL
consisting	NULL
of	NULL
a	NULL
heterodimer	NULL
of	NULL
transmembrane	NULL
glycoprotein	NULL
a	NULL
and	NULL
3	NULL
encoded	NULL
by	NULL
distinct	NULL
genes	NULL
.	NULL

As	NULL
mentioned	NULL
above	NULL
,	NULL
constitutive	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
is	NULL
restricted	NULL
to	NULL
professional	NULL
APC	NULL
such	NULL
as	NULL
dendritic	NULL
cells	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
B	NULL
lymphocytes	NULL
.	NULL

However	NULL
,	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
is	NULL
inducible	NULL
by	NULL
various	NULL
cytokines	NULL
,	NULL
of	NULL
which	NULL
the	NULL
most	NULL
potent	NULL
is	NULL
IFN-y	NULL
in	NULL
many	NULL
of	NULL
cells	NULL
such	NULL
as	NULL
fibroblasts	NULL
,	NULL
epithelial	NULL
cells	NULL
(	NULL
see	NULL
Ref	NULL
.	NULL

13	NULL
for	NULL
a	NULL
review	NULL
)	NULL
,	NULL
or	NULL
melanocytes	NULL
(	NULL
19	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
a	NULL
tissue-specific	NULL
expression	NULL
,	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
are	NULL
subject	NULL
to	NULL
a	NULL
differential	NULL
expression	NULL
depending	NULL
on	NULL
cell	NULL
activation	NULL
with	NULL
T	NULL
lymphocytes	NULL
or	NULL
differentiation	NULL
in	NULL
0022-1767/01/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
plasmocytes	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Defects	NULL
in	NULL
MHC	NULL
class	NULL
II	NULL
molecule	NULL
expression	NULL
are	NULL
responsible	NULL
for	NULL
a	NULL
severe	NULL
immunodeficiency	NULL
syndrome	NULL
(	NULL
20	NULL
)	NULL
,	NULL
while	NULL
aberrant	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
in	NULL
inappropriate	NULL
tissues	NULL
can	NULL
lead	NULL
to	NULL
autoimmune	NULL
diseases	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
requires	NULL
a	NULL
tight	NULL
control	NULL
of	NULL
regulation	NULL
.	NULL

The	NULL
genes	NULL
coding	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
isotypes	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
molecules	NULL
involved	NULL
in	NULL
Ag	NULL
presentation	NULL
such	NULL
as	NULL
HLA-DM	NULL
or	NULL
the	NULL
invariant	NULL
chain	NULL
(	NULL
I	NULL
)	NULL
,	NULL
``	NULL
are	NULL
usually	NULL
coordinately	NULL
regulated	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

22	NULL
)	NULL
.	NULL

Their	NULL
promoters	NULL
contain	NULL
conserved	NULL
motifs	NULL
,	NULL
the	NULL
W	NULL
,	NULL
X1	NULL
,	NULL
X2	NULL
,	NULL
and	NULL
Y	NULL
boxes	NULL
.	NULL

The	NULL
X1	NULL
box	NULL
binds	NULL
regulatory	NULL
factor	NULL
binding	NULL
to	NULL
X	NULL
box	NULL
(	NULL
RFX	NULL
)	NULL
,	NULL
a	NULL
heterotrimer	NULL
composed	NULL
of	NULL
RFXANK	NULL
(	NULL
23	NULL
)	NULL
,	NULL
RFX	NULL
-associated	NULL
protein	NULL
(	NULL
24	NULL
)	NULL
,	NULL
and	NULL
RFX5	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
X2	NULL
and	NULL
Y	NULL
boxes	NULL
are	NULL
binding	NULL
sites	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
a	NULL
homodimer	NULL
identified	NULL
as	NULL
CREB	NULL
(	NULL
26	NULL
)	NULL
,	NULL
and	NULL
the	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
Y	NULL
box	NULL
heterotrimer	NULL
(	NULL
27	NULL
)	NULL
.	NULL

However	NULL
,	NULL
these	NULL
ubiquitously	NULL
expressed	NULL
factors	NULL
are	NULL
not	NULL
sufficient	NULL
for	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
genes	NULL
and	NULL
their	NULL
proper	NULL
tissue-specific	NULL
expression	NULL
.	NULL

The	NULL
class	NULL
II	NULL
transactivator	NULL
(	NULL
CIITA	NULL
)	NULL
(	NULL
28	NULL
)	NULL
is	NULL
a	NULL
non-DNA-bind-ing	NULL
protein	NULL
.	NULL

Through	NULL
its	NULL
interaction	NULL
with	NULL
RFX5	NULL
,	NULL
RFXANK	NULL
,	NULL
CREB	NULL
,	NULL
two	NULL
subunits	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
Y	NULL
box	NULL
complex	NULL
,	NULL
and	NULL
the	NULL
RNA	NULL
polymerase	NULL
transcription	NULL
machinery	NULL
,	NULL
CIITA	NULL
creates	NULL
the	NULL
scaffold	NULL
required	NULL
for	NULL
a	NULL
correct	NULL
conformation	NULL
of	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
gene	NULL
promoters	NULL
and	NULL
their	NULL
transcriptional	NULL
activation	NULL
(	NULL
29	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
CIITA	NULL
confers	NULL
the	NULL
tissue-specific	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
,	NULL
with	NULL
a	NULL
constitutive	NULL
expression	NULL
in	NULL
B	NULL
lymphocytes	NULL
(	NULL
28	NULL
)	NULL
and	NULL
dendritic	NULL
cells	NULL
,	NULL
and	NULL
an	NULL
IFN-y-responsive	NULL
transcription	NULL
in	NULL
other	NULL
cell	NULL
lines	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
tissue-specific	NULL
expression	NULL
of	NULL
CIITA	NULL
,	NULL
it	NULL
was	NULL
demonstrated	NULL
that	NULL
differentiation	NULL
can	NULL
regulate	NULL
CITA	NULL
expression	NULL
,	NULL
with	NULL
the	NULL
silencing	NULL
of	NULL
CITA	NULL
transcription	NULL
in	NULL
plasmocytes	NULL
(	NULL
31	NULL
)	NULL
,	NULL
and	NULL
that	NULL
different	NULL
cytokines	NULL
can	NULL
regulate	NULL
its	NULL
expression	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
CIITA	NULL
as	NULL
a	NULL
master	NULL
switch	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
genes	NULL
has	NULL
led	NULL
to	NULL
the	NULL
analysis	NULL
of	NULL
its	NULL
transcription	NULL
.	NULL

The	NULL
CITA	NULL
gene	NULL
is	NULL
controlled	NULL
by	NULL
four	NULL
different	NULL
promoters	NULL
located	NULL
within	NULL
a	NULL
13-kb	NULL
DNA	NULL
region	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Promoter	NULL
II	NULL
has	NULL
been	NULL
described	NULL
only	NULL
in	NULL
human	NULL
cells	NULL
,	NULL
even	NULL
though	NULL
its	NULL
function	NULL
remains	NULL
yet	NULL
unknown	NULL
.	NULL

Promoters	NULL
I	NULL
and	NULL
III	NULL
drive	NULL
,	NULL
respectively	NULL
,	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
CITA	NULL
in	NULL
dendritic	NULL
cells	NULL
and	NULL
in	NULL
B	NULL
lymphocytes	NULL
(	NULL
32-34	NULL
)	NULL
,	NULL
while	NULL
the	NULL
promoter	NULL
IV	NULL
principally	NULL
controls	NULL
the	NULL
IFN-y-stimulated	NULL
transcription	NULL
of	NULL
CHTA	NULL
.	NULL

These	NULL
promoters	NULL
direct	NULL
the	NULL
transcription	NULL
of	NULL
four	NULL
different	NULL
first	NULL
exons	NULL
connected	NULL
to	NULL
a	NULL
common	NULL
second	NULL
exon	NULL
.	NULL

Both	NULL
the	NULL
second	NULL
common	NULL
exon	NULL
and	NULL
the	NULL
first	NULL
alternative	NULL
exons	NULL
expressed	NULL
from	NULL
promoters	NULL
I	NULL
and	NULL
III	NULL
contain	NULL
putative	NULL
translation	NULL
initiation	NULL
codons	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Even	NULL
though	NULL
the	NULL
second	NULL
common	NULL
exon	NULL
contains	NULL
a	NULL
translation	NULL
initiation	NULL
codon	NULL
,	NULL
the	NULL
CIITA	NULL
proteins	NULL
transcribed	NULL
from	NULL
promoters	NULL
I	NULL
and	NULL
III	NULL
might	NULL
use	NULL
upstream	NULL
ATG	NULL
located	NULL
in	NULL
the	NULL
alternative	NULL
first	NULL
exons	NULL
.	NULL

The	NULL
IFN-y	NULL
response	NULL
of	NULL
the	NULL
CIITA	NULL
gene	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
phosphor-ylation	NULL
of	NULL
STAT1	NULL
,	NULL
which	NULL
promotes	NULL
the	NULL
transcription	NULL
of	NULL
IFN	NULL
regulatory	NULL
factor-1	NULL
(	NULL
IRF-1	NULL
)	NULL
and	NULL
the	NULL
binding	NULL
of	NULL
both	NULL
IRF-1	NULL
and	NULL
STAT-1	NULL
in	NULL
association	NULL
with	NULL
USF-1	NULL
on	NULL
proximal	NULL
promoter	NULL
IV	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Transcripts	NULL
can	NULL
also	NULL
initiate	NULL
in	NULL
IFN-responsive	NULL
cells	NULL
from	NULL
promoter	NULL
III	NULL
following	NULL
a	NULL
treatment	NULL
with	NULL
the	NULL
cytokine	NULL
.	NULL

This	NULL
phenomenon	NULL
occurs	NULL
through	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
1068-bp	NULL
enhancer	NULL
element	NULL
located	NULL
~5	NULL
kb	NULL
upstream	NULL
promoter	NULL
III	NULL
(	NULL
34	NULL
)	NULL
,	NULL
to	NULL
which	NULL
we	NULL
will	NULL
refer	NULL
as	NULL
the	NULL
1-kb	NULL
enhancer	NULL
element	NULL
.	NULL

Through	NULL
this	NULL
1-kb	NULL
enhancer	NULL
element	NULL
,	NULL
the	NULL
response	NULL
to	NULL
IFN-y	NULL
induction	NULL
is	NULL
STAT-1	NULL
dependent	NULL
,	NULL
but	NULL
IRF-1	NULL
independent	NULL
(	NULL
36	NULL
)	NULL
.	NULL

*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
Ti	NULL
,	NULL
invariant	NULL
chain	NULL
;	NULL
CTA	NULL
,	NULL
class	NULL
II	NULL
transactivator	NULL
;	NULL
CSPD	NULL
,	NULL
disodium	NULL
3-	NULL
(	NULL
4-methoxyspiro	NULL
{	NULL
1,2-dioxetane-3,2	NULL
'	NULL
-	NULL
(	NULL
5'-chlera	NULL
)	NULL
tricyclo	NULL
[	NULL
3.3.1.1*	NULL
``	NULL
]	NULL
decan	NULL
}	NULL
-4-y	NULL
)	NULL
phenyl	NULL
;	NULL
Dig	NULL
,	NULL
digoxigenin	NULL
;	NULL
GBP-1	NULL
,	NULL
guanylate-binding	NULL
protein	NULL
1	NULL
;	NULL
IRF-1	NULL
,	NULL
IFN	NULL
regulatory	NULL
factor-1	NULL
;	NULL
RFX	NULL
,	NULL
regulatory	NULL
factor	NULL
binding	NULL
to	NULL
X	NULL
box	NULL
;	NULL
RLUs	NULL
,	NULL
relative	NULL
light	NULL
units	NULL
.	NULL

99	NULL
The	NULL
aim	NULL
of	NULL
our	NULL
study	NULL
is	NULL
to	NULL
understand	NULL
the	NULL
molecular	NULL
mechanisms	NULL
leading	NULL
to	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
genes	NULL
in	NULL
melanoma	NULL
.	NULL

We	NULL
will	NULL
show	NULL
in	NULL
this	NULL
work	NULL
that	NULL
this	NULL
abnormal	NULL
pattern	NULL
of	NULL
expression	NULL
is	NULL
due	NULL
to	NULL
the	NULL
constitutive	NULL
transcription	NULL
of	NULL
CHTA	NULL
from	NULL
promoter	NULL
III	NULL
,	NULL
and	NULL
is	NULL
caused	NULL
by	NULL
trans-acting	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
acting	NULL
on	NULL
the	NULL
1-kb	NULL
enhancer	NULL
element	NULL
upstream	NULL
this	NULL
promoter	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
culture	NULL
The	NULL
HT144	NULL
(	NULL
ATCC	NULL
:	NULL
HTB-63	NULL
)	NULL
,	NULL
42/95	NULL
,	NULL
M74	NULL
,	NULL
and	NULL
A375	NULL
(	NULL
ATCC	NULL
:	NULL
CRL1619	NULL
)	NULL
human	NULL
melanoma	NULL
cell	NULL
lines	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
E.	NULL
Tartour	NULL
(	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
(	NULL
INSERM	NULL
)	NULL
Unité	NULL
255	NULL
,	NULL
Curie	NULL
Institute	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
.	NULL

BUA	NULL
,	NULL
an	NULL
SV40-established	NULL
human	NULL
fibroblast	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
COM	NULL
,	NULL
an	NULL
EBV-established	NULL
human	NULL
B	NULL
lymphocyte	NULL
cell	NULL
line	NULL
,	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
for	NULL
the	NULL
IFN-y-inducible	NULL
or	NULL
constitutive	NULL
expression	NULL
of	NULL
CIITA	NULL
and	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
B.	NULL
Lisowska-Grospierre	NULL
(	NULL
INSERM	NULL
Unité	NULL
429-Hépital	NULL
Necker	NULL
)	NULL
.	NULL

All	NULL
these	NULL
cell	NULL
lines	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
,	NULL
antibiotics	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
glutamine	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
Indirect	NULL
immunofluorescence	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
FACScan	NULL
(	NULL
BD	NULL
Biosciences	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
a	NULL
CellQuest	NULL
program	NULL
on	NULL
cells	NULL
treated	NULL
for	NULL
72	NULL
h	NULL
with	NULL
250	NULL
U/ml	NULL
rIFN-y	NULL
(	NULL
PeproTech	NULL
,	NULL
Rocky	NULL
Hill	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
primary	NULL
Ab	NULL
,	NULL
the	NULL
melanoma	NULL
and	NULL
BUA	NULL
cell	NULL
lines	NULL
were	NULL
preincubated	NULL
with	NULL
pure	NULL
heat-inactivated	NULL
FCS	NULL
to	NULL
block	NULL
mAb-unspecific	NULL
binding	NULL
.	NULL

The	NULL
primary	NULL
mAbs	NULL
were	NULL
L243	NULL
(	NULL
37	NULL
)	NULL
,	NULL
B7/21	NULL
(	NULL
38	NULL
)	NULL
,	NULL
and	NULL
L2	NULL
(	NULL
39	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
directed	NULL
against	NULL
membrane	NULL
HLA-DR	NULL
,	NULL
DP	NULL
,	NULL
and	NULL
DQ	NULL
Ags	NULL
.	NULL

Human	NULL
membrane	NULL
MHC	NULL
class	NULL
I	NULL
Ags	NULL
were	NULL
detected	NULL
with	NULL
the	NULL
W6/32	NULL
mAb	NULL
(	NULL
Serotec	NULL
,	NULL
Oxford	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

Cell	NULL
labeling	NULL
was	NULL
then	NULL
performed	NULL
with	NULL
the	NULL
anti-mouse	NULL
Ig	NULL
labeled	NULL
with	NULL
FITC	NULL
from	NULL
Biosys	NULL
(	NULL
Compiegne	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Cell	NULL
transfections	NULL
,	NULL
luciferase	NULL
constructs	NULL
,	NULL
and	NULL
assays	NULL
Melanoma	NULL
cell	NULL
lines	NULL
were	NULL
plated	NULL
at	NULL
a	NULL
density	NULL
of	NULL
4	NULL
X	NULL
10°	NULL
cells/well	NULL
in	NULL
six-well	NULL
plates	NULL
.	NULL

Twenty-four	NULL
hours	NULL
later	NULL
,	NULL
semiconfluent	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
a	NULL
5:1	NULL
molar	NULL
ratio	NULL
of	NULL
a	NULL
luciferase	NULL
construct	NULL
and	NULL
pON1	NULL
plasmid	NULL
.	NULL

pON1	NULL
encodes	NULL
the	NULL
B-galactosidase	NULL
gene	NULL
placed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter	NULL
(	NULL
40	NULL
)	NULL
,	NULL
and	NULL
allows	NULL
the	NULL
monitoring	NULL
of	NULL
transfection	NULL
efficiency	NULL
.	NULL

The	NULL
transfection	NULL
of	NULL
the	NULL
melanoma	NULL
cell	NULL
lines	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
Effecten	NULL
Reagent	NULL
(	NULL
Qiagen	NULL
,	NULL
Chatsworth	NULL
,	NULL
CA	NULL
)	NULL
following	NULL
the	NULL
instructions	NULL
of	NULL
the	NULL
manufacturer	NULL
.	NULL

Twenty	NULL
hours	NULL
later	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFN-y	NULL
for	NULL
24	NULL
h.	NULL
Luciferase	NULL
and	NULL
B-galactosidase	NULL
activities	NULL
were	NULL
assayed	NULL
using	NULL
the	NULL
Luciferase	NULL
Assay	NULL
System	NULL
and	NULL
the	NULL
B-galactosidase	NULL
Enzyme	NULL
Assay	NULL
System	NULL
kits	NULL
from	NULL
Promega	NULL
(	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
,	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
BioOrbit	NULL
lumino-meter	NULL
.	NULL

Relative	NULL
light	NULL
units	NULL
per	NULL
second	NULL
(	NULL
RLUs_	NULL
'	NULL
)	NULL
were	NULL
further	NULL
divided	NULL
by	NULL
the	NULL
B-galactosidase	NULL
activities	NULL
(	NULL
expressed	NULL
as	NULL
A420	NULL
)	NULL
to	NULL
correct	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

The	NULL
pGL3-control	NULL
,	NULL
containing	NULL
an	NULL
SV40	NULL
promoter	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
gene	NULL
,	NULL
and	NULL
the	NULL
promoterless	NULL
pGL3-basic	NULL
and	NULL
pGL2-basic	NULL
constructs	NULL
were	NULL
from	NULL
Promega	NULL
.	NULL

The	NULL
pGL3-DRA	NULL
,	NULL
pGL3-DQA	NULL
,	NULL
and	NULL
pGL3-DPA	NULL
plasmids	NULL
contain	NULL
250-bp	NULL
promoter	NULL
fragments	NULL
of	NULL
the	NULL
HLA-D	NULL
genes	NULL
,	NULL
which	NULL
include	NULL
the	NULL
conserved	NULL
W	NULL
,	NULL
X1	NULL
,	NULL
X2	NULL
,	NULL
and	NULL
Y	NULL
boxes	NULL
(	NULL
41	NULL
)	NULL
.	NULL

The	NULL
human	NULL
CHITAp-D2	NULL
vector	NULL
(	NULL
42	NULL
)	NULL
containing	NULL
the	NULL
minimal	NULL
promoter	NULL
IV	NULL
of	NULL
CHTA	NULL
cloned	NULL
in	NULL
the	NULL
pGL2-basic	NULL
vector	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
E.	NULL
Benveniste	NULL
(	NULL
University	NULL
of	NULL
Alabama	NULL
,	NULL
Birmingham	NULL
,	NULL
AL	NULL
)	NULL
.	NULL

The	NULL
CHITA-1783-luc	NULL
construct	NULL
contains	NULL
1783	NULL
bp	NULL
of	NULL
promoter	NULL
III	NULL
of	NULL
CHTA	NULL
cloned	NULL
in	NULL
the	NULL
pGL3-basic	NULL
vector	NULL
(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
pHCIITA.Luc	NULL
,	NULL
pHIDEL2.CITA.Luc	NULL
,	NULL
pHIDEL3.CIHITA.Luc	NULL
,	NULL
and	NULL
pHIDELA4	NULL
.	NULL

constructs	NULL
were	NULL
described	NULL
previously	NULL
(	NULL
34	NULL
,	NULL
36	NULL
)	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

9	NULL
as	NULL
well	NULL
)	NULL
.	NULL

The	NULL
construct	NULL
corresponds	NULL
to	NULL
the	NULL
plIIDEL2	NULL
.	NULL

CIITA.Luc	NULL
plasmid	NULL
mutagenized	NULL
to	NULL
replace	NULL
the	NULL
consensus	NULL
Brm-2/N-Oct3	NULL
binding	NULL
site	NULL
(	NULL
CATGCAAAATG	NULL
)	NULL
located	NULL
in	NULL
the	NULL
enhancer	NULL
with	NULL
the	NULL
CATG	NULL
CAGCATG	NULL
sequence	NULL
demonstrated	NULL
to	NULL
inactivate	NULL
Bm-2	NULL
binding	NULL
(	NULL
43	NULL
)	NULL
.	NULL

The	NULL
mutagenesis	NULL
was	NULL
performed	NULL
,	NULL
following	NULL
the	NULL
instructions	NULL
of	NULL
the	NULL
manufacturer	NULL
with	NULL
the	NULL
Quick	NULL
Change	NULL
site-directed	NULL
mutagenesis	NULL
kit	NULL
from	NULL
Stratagene	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
using	NULL
the	NULL
following	NULL
primer	NULL
(	NULL
5-TCTAGACACCTACCCCATGCAG	NULL
CATGCAGTGCTGAGTGCT-3	NULL
``	NULL
)	NULL
.	NULL

A	NULL
deletion	NULL
in	NULL
the	NULL
same	NULL
site	NULL
removing	NULL
the	NULL
AAAAT	NULL
half	NULL
of	NULL
the	NULL
palindrome	NULL
was	NULL
created	NULL
in	NULL
the	NULL
pIIDEL2.Bm-Del.Luec	NULL
construct	NULL
,	NULL
following	NULL
the	NULL
same	NULL
procedure	NULL
with	NULL
the	NULL
primer	NULL
GACACCTACCCCATGCTGCAGTGCTGAGTGCTITTGGGTACT-3	NULL
'	NULL
.	NULL

The	NULL
pGL3-SV40.Enh	NULL
construct	NULL
was	NULL
generated	NULL
through	NULL
the	NULL
ligation	NULL
of	NULL
the	NULL
Secl-linearized	NULL
pGL3-control	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
a	NULL
2132-bp	NULL
PCR	NULL
product	NULL
containing	NULL
the	NULL
enhancer	NULL
upstream	NULL
promoter	NULL
III	NULL
of	NULL
the	NULL
CHTA	NULL
gene	NULL
.	NULL

The	NULL
construct	NULL
was	NULL
cotransfected	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
,	NULL
using	NULL
Effecten	NULL
as	NULL
described	NULL
above	NULL
,	NULL
with	NULL
a	NULL
Renilla	NULL
luciferase	NULL
reporter	NULL
construct	NULL
(	NULL
pRL-TK	NULL
vector	NULL
from	NULL
Promega	NULL
)	NULL
to	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
(	NULL
molar	NULL
ratio	NULL
1:5	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
100	NULL
ABNORMAL	NULL
TRANSCRIPTION	NULL
OF	NULL
CIITA	NULL
IN	NULL
MELANOMA	NULL
CELL	NULL
LINES	NULL
Renilla/Firefly	NULL
vectors	NULL
)	NULL
.	NULL

The	NULL
luciferase	NULL
activities	NULL
were	NULL
measured	NULL
with	NULL
the	NULL
Dual	NULL
Luciferase	NULL
Assay	NULL
System	NULL
from	NULL
Promega	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
subconfluent	NULL
cultures	NULL
with	NULL
TRIzol	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
following	NULL
the	NULL
instructions	NULL
of	NULL
the	NULL
manufacturer	NULL
.	NULL

cDNA	NULL
preparation	NULL
was	NULL
performed	NULL
on	NULL
1	NULL
ug	NULL
total	NULL
RNA	NULL
with	NULL
poly	NULL
(	NULL
dT	NULL
)	NULL
and	NULL
2.5	NULL
U	NULL
Om-niscript	NULL
reverse	NULL
transcriptase	NULL
from	NULL
Qiagen	NULL
.	NULL

PCR	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
Taq	NULL
polymerase	NULL
from	NULL
Qiagen	NULL
following	NULL
the	NULL
instructions	NULL
of	NULL
the	NULL
manufacturer	NULL
.	NULL

Quantification	NULL
of	NULL
cDNA	NULL
concentration	NULL
was	NULL
further	NULL
assessed	NULL
with	NULL
GAPDH-specific	NULL
primers	NULL
through	NULL
a	NULL
16-cycle	NULL
PCR	NULL
.	NULL

The	NULL
oligonucleotide	NULL
sequences	NULL
and	NULL
amplification	NULL
conditions	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
I	NULL
.	NULL

For	NULL
all	NULL
these	NULL
primer	NULL
sets	NULL
,	NULL
1-min	NULL
denaturation	NULL
,	NULL
annealing	NULL
,	NULL
and	NULL
extension	NULL
were	NULL
applied	NULL
during	NULL
the	NULL
PCR	NULL
and	NULL
performed	NULL
in	NULL
a	NULL
MG	NULL
apparatus	NULL
.	NULL

Semiquantitative	NULL
PCR	NULL
of	NULL
promoter-specific	NULL
CITA	NULL
transcripts	NULL
was	NULL
performed	NULL
by	NULL
labeling	NULL
of	NULL
cDNA	NULL
products	NULL
during	NULL
the	NULL
PCR	NULL
amplification	NULL
using	NULL
digoxigenin	NULL
(	NULL
Dig	NULL
)	NULL
-dUTP	NULL
(	NULL
Roche	NULL
,	NULL
Meyland	NULL
,	NULL
France	NULL
)	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
transferred	NULL
on	NULL
membrane	NULL
Hybond	NULL
N*	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
and	NULL
revealed	NULL
with	NULL
ready-to-use	NULL
CSPD	NULL
(	NULL
Roche	NULL
)	NULL
.	NULL

The	NULL
sense	NULL
primers	NULL
,	NULL
pH-CHITA	NULL
(	NULL
GGAATTCCAGACTCCGGGAGCTGCTGC	NULL
)	NULL
and	NULL
pIV-	NULL
CHITA	NULL
(	NULL
CCCAGAGCTGGCGGGAGGGA	NULL
)	NULL
,	NULL
were	NULL
both	NULL
used	NULL
in	NULL
association	NULL
with	NULL
the	NULL
antisense	NULL
CHITA-P-AS	NULL
primer	NULL
(	NULL
TGCTGAACTGGTCGCAGTTGATGG	NULL
)	NULL
.	NULL

For	NULL
plll-initiated	NULL
transcripts	NULL
,	NULL
25-cycle	NULL
amplification	NULL
was	NULL
performed	NULL
at	NULL
annealing	NULL
temperatures	NULL
of	NULL
67°C	NULL
.	NULL

For	NULL
pIV-initiated	NULL
transcripts	NULL
,	NULL
27	NULL
cycles	NULL
were	NULL
applied	NULL
,	NULL
with	NULL
a	NULL
60°C	NULL
annealing	NULL
temperature	NULL
.	NULL

RACE-PCR	NULL
The	NULL
RACE-PCR	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
5	NULL
``	NULL
RACE	NULL
system	NULL
from	NULL
Life	NULL
Technologies	NULL
(	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
cDNA	NULL
preparation	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
CIITA-P-AS	NULL
oligonucleotide	NULL
described	NULL
above	NULL
,	NULL
which	NULL
hybridizes	NULL
to	NULL
all	NULL
forms	NULL
of	NULL
CITA	NULL
transcripts	NULL
.	NULL

The	NULL
antisense	NULL
oligonucleotide	NULL
specific	NULL
for	NULL
promoter	NULL
III-initiated	NULL
transcripts	NULL
(	NULL
CTGACAGGTAGGACCCAGC	NULL
)	NULL
was	NULL
used	NULL
in	NULL
association	NULL
with	NULL
the	NULL
anchored	NULL
primer	NULL
from	NULL
the	NULL
kit	NULL
,	NULL
with	NULL
a	NULL
56°C	NULL
annealing	NULL
temperature	NULL
and	NULL
a	NULL
35-cycle	NULL
amplification	NULL
.	NULL

The	NULL
RACE-PCR	NULL
products	NULL
(	NULL
200	NULL
pb	NULL
)	NULL
were	NULL
directly	NULL
sub-cloned	NULL
in	NULL
the	NULL
PCR2.1	NULL
vector	NULL
(	NULL
TA-cloning	NULL
kit	NULL
from	NULL
Invitrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
the	NULL
inserts	NULL
were	NULL
sequenced	NULL
using	NULL
the	NULL
Big	NULL
Dye	NULL
Terminator	NULL
cycle-sequencing	NULL
kit	NULL
(	NULL
Perkin	NULL
Elmer	NULL
Applied	NULL
Biosystems	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
an	NULL
ABI	NULL
377	NULL
automatic	NULL
sequencer	NULL
(	NULL
Perkin-Elmer	NULL
,	NULL
Norwalk	NULL
,	NULL
CT	NULL
)	NULL
.	NULL

Results	NULL
Coordinated	NULL
HLA-D	NULL
isotype	NULL
expression	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
of	NULL
HLA-DR¢	NULL
melanoma	NULL
cell	NULL
lines	NULL
Cell	NULL
surface	NULL
expression	NULL
of	NULL
HLA-DR	NULL
molecules	NULL
was	NULL
analyzed	NULL
on	NULL
a	NULL
panel	NULL
of	NULL
20	NULL
different	NULL
melanoma	NULL
cell	NULL
lines	NULL
by	NULL
cytofluorometry	NULL
.	NULL

As	NULL
previously	NULL
described	NULL
by	NULL
others	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
,	NULL
two	NULL
main	NULL
phenotypes	NULL
were	NULL
obtained	NULL
,	NULL
with	NULL
either	NULL
no	NULL
expression	NULL
of	NULL
HLA-DR	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
treatment	NULL
(	NULL
HLA-DR~	NULL
cells	NULL
)	NULL
,	NULL
or	NULL
constitutive	NULL
expression	NULL
of	NULL
these	NULL
molecules	NULL
(	NULL
HLA-DR	NULL
*	NULL
cells	NULL
)	NULL
.	NULL

These	NULL
phenotypes	NULL
are	NULL
exemplified	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
for	NULL
the	NULL
42/95	NULL
and	NULL
HT144	NULL
cell	NULL
lines	NULL
.	NULL

This	NULL
study	NULL
was	NULL
further	NULL
pursued	NULL
,	NULL
on	NULL
four	NULL
melanoma	NULL
cell	NULL
lines	NULL
considered	NULL
as	NULL
prototypes	NULL
in	NULL
our	NULL
study	NULL
,	NULL
with	NULL
the	NULL
analysis	NULL
of	NULL
all	NULL
three	NULL
HLA-D	NULL
isotype	NULL
expression	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

In	NULL
two	NULL
HLA-DR~	NULL
cell	NULL
lines	NULL
,	NULL
42/95	NULL
and	NULL
M74	NULL
,	NULL
none	NULL
of	NULL
the	NULL
three	NULL
isotypes	NULL
was	NULL
expressed	NULL
in	NULL
a	NULL
constitutive	NULL
manner	NULL
.	NULL

However	NULL
,	NULL
IFN-y	NULL
treatment	NULL
induced	NULL
the	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
HLA-DR	NULL
and	NULL
HLA-DP	NULL
,	NULL
with	NULL
a	NULL
null	NULL
or	NULL
very	NULL
weak	NULL
expression	NULL
of	NULL
HLA-DQ	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
melanoma	NULL
cell	NULL
lines	NULL
have	NULL
a	NULL
pattern	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
similar	NULL
to	NULL
fibroblast	NULL
cell	NULL
lines	NULL
(	NULL
BUA	NULL
,	NULL
Table	NULL
II	NULL
)	NULL
or	NULL
to	NULL
epidermal	NULL
melanocytes	NULL
(	NULL
19	NULL
)	NULL
.	NULL

With	NULL
the	NULL
HLA-DR*	NULL
cell	NULL
lines	NULL
,	NULL
HT144	NULL
and	NULL
A375	NULL
,	NULL
all	NULL
three	NULL
isotypes	NULL
were	NULL
expressed	NULL
constitutively	NULL
,	NULL
with	NULL
a	NULL
further	NULL
stimulation	NULL
of	NULL
expression	NULL
following	NULL
the	NULL
IFN-y	NULL
treat-ment	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
deregulation	NULL
of	NULL
HLA-DR	NULL
molecule	NULL
expression	NULL
in	NULL
these	NULL
melanoma	NULL
cell	NULL
lines	NULL
is	NULL
also	NULL
affecting	NULL
HLA-DP	NULL
and	NULL
HLA-DQ	NULL
.	NULL

However	NULL
,	NULL
constitutive	NULL
and	NULL
IFN-induced	NULL
MHC	NULL
class	NULL
I	NULL
expression	NULL
did	NULL
not	NULL
differ	NULL
significantly	NULL
when	NULL
HLA-DR~	NULL
and	NULL
HLA-DR	NULL
*	NULL
cell	NULL
lines	NULL
were	NULL
compared	NULL
,	NULL
thereby	NULL
suggesting	NULL
that	NULL
the	NULL
phenomenon	NULL
is	NULL
specific	NULL
for	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
.	NULL

Constitutive	NULL
expression	NULL
of	NULL
the	NULL
HLA-D	NULL
transcripts	NULL
in	NULL
the	NULL
HLA-DR	NULL
melanoma	NULL
cell	NULL
lines	NULL
The	NULL
expression	NULL
of	NULL
the	NULL
HLA-D	NULL
transcripts	NULL
was	NULL
analyzed	NULL
by	NULL
RT-PCR	NULL
experiments	NULL
in	NULL
the	NULL
four	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
melanocyte	NULL
cell	NULL
line	NULL
,	NULL
we	NULL
used	NULL
as	NULL
a	NULL
control	NULL
the	NULL
BUA	NULL
fibroblast	NULL
cell	NULL
line	NULL
.	NULL

As	NULL
displayed	NULL
on	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
constitutive	NULL
expression	NULL
of	NULL
all	NULL
the	NULL
Table	NULL
I.	NULL
Sequence	NULL
,	NULL
annealing	NULL
temperatures	NULL
,	NULL
and	NULL
amplification	NULL
cycles	NULL
applied	NULL
for	NULL
each	NULL
set	NULL
of	NULL
primers	NULL
used	NULL
in	NULL
the	NULL
RT-PCR	NULL
experiments	NULL
``	NULL
Annealing	NULL
Temperature	NULL
No	NULL
.	NULL

of	NULL
Amplified	NULL
cDNA	NULL
Primer	NULL
Set	NULL
(	NULL
°C	NULL
)	NULL
Cycles	NULL
HLA-DRA	NULL
S	NULL
TGGGAGTTTGATGTCCCAAG	NULL
58	NULL
25	NULL
AS	NULL
-	NULL
AACATCATCACCTCCATGTG	NULL
HLA-DRB	NULL
S	NULL
CAGCATTRAAGTCAGGTGGTTCC	NULL
65	NULL
28	NULL
AS	NULL
-	NULL
CTCAGCATCTTGCTCTGTGCAG	NULL
HLA-DQA	NULL
S	NULL
GTGCTGCAGGTGTAAACTTGTACCAG	NULL
58	NULL
25	NULL
AS	NULL
-	NULL
CACGGATCCGGTAGCAGCGGTAGAGTTG	NULL
HLA-DQB	NULL
S	NULL
CGAGTACTGGAAYAGCCAGAAGG	NULL
59	NULL
25	NULL
AS	NULL
-	NULL
GGAGTCATTTCCAGCATCACCAGG	NULL
HLA-DPA	NULL
S	NULL
GGAGACCGTCTGGCATCTGGA	NULL
58	NULL
25	NULL
AS	NULL
-	NULL
CTCTCAGCGACACCCTCAGT	NULL
HLA-DPB	NULL
S	NULL
GGGACACAGCGCTTCCTGGAG	NULL
59	NULL
25	NULL
AS	NULL
-	NULL
CAAGCAGGTTGTGGTGCTGCA	NULL
HLA-DMB	NULL
S	NULL
GGCTGACTGTTACTTCACCA	NULL
54	NULL
33	NULL
AS	NULL
-	NULL
CCTTCTCACTTGGAGTGGA	NULL
Ii	NULL
S	NULL
ATCTTTACAGAGCAGAGCAT	NULL
65	NULL
28	NULL
AS	NULL
-	NULL
CCAGATCCTGCTTGGTCAC	NULL
GAPDH	NULL
S	NULL
GTCGTATTGGGCGCCTGGTCAC	NULL
62	NULL
16	NULL
AS	NULL
-	NULL
CACGACGTACTCAGCGCCAGCA	NULL
CHTA	NULL
S	NULL
TTTCTGGGCACCCGCCTCAC	NULL
62	NULL
33	NULL
AS	NULL
-	NULL
CTGGGGGAAGGTGGCTGAGA	NULL
IRF-1	NULL
S	NULL
CTTCCCTCTTCCACTCGGAGTC	NULL
63	NULL
25	NULL
AS	NULL
-	NULL
CTGGTCTTTCACCTCCTCGATATCT	NULL
*	NULL
S	NULL
,	NULL
Sense	NULL
;	NULL
AS	NULL
,	NULL
antisense	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
:	NULL
4PM	NULL
,	NULL
A	NULL
a	NULL
B	NULL
Number	NULL
of	NULL
events	NULL
Fluorescence	NULL
intensity	NULL
FIGURE	NULL
1	NULL
.	NULL

Cell	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
HLA-DR	NULL
molecules	NULL
in	NULL
the	NULL
42/95	NULL
and	NULL
HT144	NULL
melanoma	NULL
cell	NULL
lines	NULL
examined	NULL
by	NULL
indirect	NULL
immunoflu-orescence	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
either	NULL
treated	NULL
with	NULL
250	NULL
U/ml	NULL
IFN-y	NULL
for	NULL
48	NULL
h	NULL
or	NULL
untreated	NULL
as	NULL
indicated	NULL
on	NULL
the	NULL
figure	NULL
(	NULL
light	NULL
histograms	NULL
)	NULL
.	NULL

The	NULL
dark	NULL
histogram	NULL
corresponds	NULL
to	NULL
the	NULL
isotypic	NULL
control	NULL
.	NULL

The	NULL
L243	NULL
mAb	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
the	NULL
expression	NULL
of	NULL
HLA-DR	NULL
molecules	NULL
by	NULL
cytofluorometry	NULL
.	NULL

HLA-D	NULL
mRNAs	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
Ii	NULL
,	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
HT144	NULL
and	NULL
A375	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
with	NULL
the	NULL
BUA	NULL
and	NULL
42/95	NULL
cells	NULL
,	NULL
no	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
treatment	NULL
,	NULL
except	NULL
HLA-DPB	NULL
and	NULL
HLA-DQB	NULL
transcripts	NULL
detected	NULL
in	NULL
the	NULL
untreated	NULL
BUA	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
M74	NULL
cell	NULL
line	NULL
was	NULL
more	NULL
puzzling	NULL
,	NULL
as	NULL
several	NULL
genes	NULL
displayed	NULL
a	NULL
constitutive	NULL
expression	NULL
(	NULL
HLA-DRB	NULL
,	NULL
HLA-DQB	NULL
,	NULL
HLA-DMB	NULL
,	NULL
HLA-DPA	NULL
,	NULL
and	NULL
HLA-DPB	NULL
)	NULL
,	NULL
even	NULL
though	NULL
HLA-DRA	NULL
,	NULL
HLA-DQA	NULL
,	NULL
and	NULL
Ii	NULL
mRNAs	NULL
were	NULL
not	NULL
detected	NULL
,	NULL
even	NULL
with	NULL
a	NULL
30-cycle	NULL
amplification	NULL
RT-PCR	NULL
procedure	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
abnormal	NULL
constitutive	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
HLA-D	NULL
molecules	NULL
in	NULL
the	NULL
HLA-DR	NULL
*	NULL
melanoma	NULL
cell	NULL
lines	NULL
is	NULL
in	NULL
good	NULL
agreement	NULL
with	NULL
a	NULL
transcriptional	NULL
deregulation	NULL
of	NULL
their	NULL
encoding	NULL
genes	NULL
.	NULL

Luciferase	NULL
gene	NULL
reporter	NULL
assays	NULL
were	NULL
next	NULL
performed	NULL
with	NULL
HLA-DRA	NULL
,	NULL
HLA-DPA	NULL
,	NULL
and	NULL
HLA-DQA	NULL
promoter	NULL
constructs	NULL
in	NULL
the	NULL
HT144	NULL
and	NULL
42/95	NULL
cell	NULL
lines	NULL
.	NULL

As	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
treatment	NULL
,	NULL
luciferase	NULL
activities	NULL
driven	NULL
by	NULL
the	NULL
HLA-D	NULL
gene	NULL
promoters	NULL
were	NULL
systematically	NULL
greater	NULL
(	NULL
50-	NULL
to	NULL
180-fold	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
promoter	NULL
)	NULL
in	NULL
the	NULL
HLA-DR	NULL
*	NULL
HT144	NULL
cell	NULL
line	NULL
than	NULL
in	NULL
the	NULL
HLA-DR~	NULL
42/95	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
data	NULL
show	NULL
that	NULL
the	NULL
deregulation	NULL
of	NULL
the	NULL
HLA-D	NULL
molecules	NULL
is	NULL
caused	NULL
by	NULL
a	NULL
factor	NULL
activating	NULL
the	NULL
coordinate	NULL
transcription	NULL
of	NULL
the	NULL
HLA-D	NULL
genes	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
IFN-y	NULL
stimulation	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
HLA-D	NULL
promoter	NULL
luciferase	NULL
constructs	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
was	NULL
very	NULL
low	NULL
.	NULL

As	NULL
an	NULL
example	NULL
,	NULL
with	NULL
the	NULL
HLA-DRA	NULL
promoter	NULL
construct	NULL
,	NULL
stimulation	NULL
following	NULL
the	NULL
IFN-y	NULL
treatment	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
was	NULL
1.4-fold	NULL
,	NULL
while	NULL
it	NULL
was	NULL
6-fold	NULL
with	NULL
the	NULL
42/95	NULL
cell	NULL
line	NULL
or	NULL
16-fold	NULL
in	NULL
the	NULL
BUA	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
weak	NULL
IFN-y	NULL
response	NULL
correlates	NULL
with	NULL
the	NULL
poor	NULL
response	NULL
to	NULL
the	NULL
cytokine	NULL
previously	NULL
observed	NULL
in	NULL
the	NULL
analysis	NULL
of	NULL
most	NULL
HLA-D	NULL
transcripts	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

101	NULL
HLA-DR	NULL
42195	NULL
|	NULL
M74	NULL
BUA	NULL
|	NULL
A375	NULL
IFNy	NULL
1004	NULL
[	NULL
O-	NULL
c+	NULL
-	NULL
__+	NULL
-	NULL
__+	NULL
-	NULL
__+	NULL
or	NULL
»	NULL
.	NULL

|	NULL
ees	NULL
ees	NULL
tar	NULL
``	NULL
ac	NULL
pa	NULL
cee	NULL
Meeps	NULL
oy	NULL
ar	NULL
e	NULL
a	NULL
co	NULL
_|	NULL
Wilion	NULL
)	NULL
(	NULL
=+	NULL
==	NULL
)	NULL
fne	NULL
C	NULL
ss	NULL
)	NULL
__	NULL
-	NULL
_C	NULL
vce	NULL
|E	NULL
a	NULL
rrr	NULL
j	NULL
nos	NULL
|	NULL
liken	NULL
:	NULL
tikes	NULL
|	NULL
--	NULL
]	NULL
HLA-DR+	NULL
HT144	NULL
GAPDH	NULL
|	NULL
ean	NULL
emm	NULL
emsems	NULL
cos	NULL
cs	NULL
:	NULL
can	NULL
am	NULL
cs	NULL
cus	NULL
FIGURE	NULL
2	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
of	NULL
HLA-D	NULL
gene	NULL
transcription	NULL
in	NULL
the	NULL
four	NULL
melanoma	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
the	NULL
BUA	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
number	NULL
of	NULL
amplification	NULL
cycles	NULL
is	NULL
given	NULL
for	NULL
each	NULL
primer	NULL
set	NULL
in	NULL
Table	NULL
I.	NULL
cDNAs	NULL
either	NULL
from	NULL
cells	NULL
treated	NULL
for	NULL
48	NULL
h	NULL
with	NULL
250	NULL
U/ml	NULL
IFN-y	NULL
(	NULL
+	NULL
)	NULL
or	NULL
from	NULL
untreated	NULL
cells	NULL
(	NULL
-	NULL
)	NULL
and	NULL
the	NULL
PCR	NULL
products	NULL
were	NULL
analyzed	NULL
on	NULL
ethidium	NULL
bromide-stained	NULL
agarose	NULL
gels	NULL
.	NULL

To	NULL
assess	NULL
that	NULL
equal	NULL
amounts	NULL
of	NULL
cDNA	NULL
were	NULL
used	NULL
,	NULL
a	NULL
16-cycle	NULL
amplification	NULL
was	NULL
performed	NULL
on	NULL
the	NULL
cDNAs	NULL
with	NULL
GAPDH	NULL
primers	NULL
,	NULL
and	NULL
the	NULL
corresponding	NULL
Dig-labeled	NULL
PCR	NULL
products	NULL
were	NULL
stained	NULL
with	NULL
CSPD	NULL
.	NULL

CHTA	NULL
is	NULL
constitutively	NULL
transcribed	NULL
in	NULL
both	NULL
HLA-DR¢*	NULL
melanoma	NULL
cell	NULL
lines	NULL
As	NULL
CHITA	NULL
is	NULL
the	NULL
master	NULL
switch	NULL
of	NULL
the	NULL
tissue-specific	NULL
expression	NULL
pattern	NULL
of	NULL
the	NULL
HLA-D	NULL
molecules	NULL
and	NULL
of	NULL
the	NULL
accessory	NULL
proteins	NULL
implicated	NULL
in	NULL
Ag	NULL
processing	NULL
,	NULL
we	NULL
have	NULL
next	NULL
analyzed	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
CHTA	NULL
mRNA	NULL
in	NULL
the	NULL
four	NULL
melanoma	NULL
cell	NULL
lines	NULL
by	NULL
RT-PCR	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
described	NULL
by	NULL
others	NULL
for	NULL
fibroblast	NULL
or	NULL
melanoma	NULL
cell	NULL
lines	NULL
(	NULL
32	NULL
)	NULL
,	NULL
in	NULL
the	NULL
BUA	NULL
and	NULL
42/95	NULL
cell	NULL
lines	NULL
,	NULL
CIFTA	NULL
mRNA	NULL
was	NULL
not	NULL
detected	NULL
unless	NULL
a	NULL
6-h	NULL
IFN-y	NULL
treatment	NULL
was	NULL
applied	NULL
,	NULL
even	NULL
though	NULL
a	NULL
33-cycle	NULL
PCR	NULL
was	NULL
applied	NULL
on	NULL
the	NULL
cDNAs	NULL
.	NULL

In	NULL
the	NULL
HLA-DR~	NULL
M74	NULL
cell	NULL
line	NULL
,	NULL
a	NULL
very	NULL
faint	NULL
band	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
untreated	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
both	NULL
HLA-DR	NULL
*	NULL
cell	NULL
lines	NULL
,	NULL
HT144	NULL
and	NULL
A375	NULL
,	NULL
CIHTA	NULL
transcripts	NULL
were	NULL
observed	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
cytokine	NULL
.	NULL

CHTA	NULL
transcription	NULL
is	NULL
inducible	NULL
by	NULL
IFN-y	NULL
in	NULL
all	NULL
these	NULL
cell	NULL
lines	NULL
when	NULL
using	NULL
lower	NULL
number	NULL
of	NULL
amplification	NULL
cycles	NULL
(	NULL
see	NULL
be-low	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
expression	NULL
pattern	NULL
of	NULL
CITA	NULL
transcript	NULL
was	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
phenotype	NULL
,	NULL
thereby	NULL
indicating	NULL
that	NULL
the	NULL
HLA-DR	NULL
*	NULL
phenotype	NULL
is	NULL
highly	NULL
likely	NULL
caused	NULL
by	NULL
the	NULL
abnormal	NULL
constitutive	NULL
expression	NULL
of	NULL
CIITA	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
IFN-y	NULL
transduction	NULL
pathway	NULL
in	NULL
HT144	NULL
Based	NULL
on	NULL
data	NULL
cited	NULL
above	NULL
regarding	NULL
the	NULL
weak	NULL
IFN-y	NULL
response	NULL
observed	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
concerning	NULL
the	NULL
HLA-D	NULL
genes	NULL
,	NULL
we	NULL
Table	NULL
II	NULL
.	NULL

Summary	NULL
of	NULL
the	NULL
data	NULL
obtained	NULL
by	NULL
flow	NULL
cytometry	NULL
on	NULL
the	NULL
melanoma	NULL
cell	NULL
lines	NULL
and	NULL
on	NULL
control	NULL
cells	NULL
,	NULL
the	NULL
B	NULL
lymphocyte	NULL
COM	NULL
,	NULL
and	NULL
the	NULL
fibroblast	NULL
BUA	NULL
cell	NULL
lines	NULL
``	NULL
HLA-DR	NULL
HLA-DP	NULL
HLA-DQ	NULL
HLA-A.B.C	NULL
Cell	NULL
line	NULL
UNT	NULL
IFN-y	NULL
UNT	NULL
IFN-y	NULL
UNT	NULL
IFN-y	NULL
UNT	NULL
IFN-y	NULL
42195	NULL
-	NULL
++	NULL
-	NULL
+	NULL
-	NULL
-	NULL
++	NULL
+++	NULL
M74	NULL
-	NULL
+++	NULL
-	NULL
++	NULL
-	NULL
-	NULL
++	NULL
+++	NULL
BUA	NULL
-	NULL
+++	NULL
-	NULL
++	NULL
-	NULL
-	NULL
++	NULL
+++	NULL
COM	NULL
++++	NULL
ND	NULL
++++	NULL
ND	NULL
++++	NULL
ND	NULL
++++	NULL
ND	NULL
A375	NULL
++	NULL
+++	NULL
+	NULL
++	NULL
+	NULL
++	NULL
++	NULL
+++	NULL
HT144	NULL
+++	NULL
++++	NULL
++	NULL
+++	NULL
++	NULL
+++	NULL
+++	NULL
++++	NULL
``	NULL
Cells	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
UNT	NULL
)	NULL
or	NULL
treated	NULL
for	NULL
72	NULL
h	NULL
with	NULL
IFN-y	NULL
,	NULL
and	NULL
indirect	NULL
immunofluorescence	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
L243	NULL
,	NULL
B7/21	NULL
,	NULL
L2	NULL
,	NULL
and	NULL
W6/32	NULL
mAbs	NULL
directed	NULL
,	NULL
respectively	NULL
,	NULL
against	NULL
HLA-DR	NULL
,	NULL
HLA-DP	NULL
,	NULL
HLA-DQ	NULL
,	NULL
or	NULL
HLA-A	NULL
,	NULL
B	NULL
,	NULL
C	NULL
.	NULL

The	NULL
+	NULL
and	NULL
-	NULL
symbols	NULL
correspond	NULL
to	NULL
the	NULL
following	NULL
fluorescence	NULL
means	NULL
:	NULL
-	NULL
,	NULL
1-3	NULL
;	NULL
+	NULL
,	NULL
>	NULL
3-20	NULL
;	NULL
++	NULL
,	NULL
>	NULL
20-100	NULL
;	NULL
+++	NULL
,	NULL
>	NULL
100-400	NULL
;	NULL
++++	NULL
,	NULL
>	NULL
400	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
102	NULL
ABNORMAL	NULL
TRANSCRIPTION	NULL
OF	NULL
CIITA	NULL
IN	NULL
MELANOMA	NULL
CELL	NULL
LINES	NULL
hypothesized	NULL
that	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
CIITA	NULL
might	NULL
result	NULL
from	NULL
a	NULL
permanent	NULL
activation	NULL
of	NULL
the	NULL
IFN-y	NULL
transduction	NULL
pathway	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
might	NULL
therefore	NULL
lead	NULL
to	NULL
a	NULL
poor	NULL
additional	NULL
response	NULL
to	NULL
the	NULL
cytokine	NULL
.	NULL

Two	NULL
IFN-y-response	NULL
genes	NULL
were	NULL
then	NULL
analyzed	NULL
for	NULL
their	NULL
transcription	NULL
in	NULL
the	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

IRF-I	NULL
is	NULL
an	NULL
early	NULL
response	NULL
gene	NULL
induced	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
phosphor-ylated	NULL
STAT-1	NULL
heterodimer	NULL
,	NULL
and	NULL
guanylate-binding	NULL
protein	NULL
1	NULL
(	NULL
GBP-1	NULL
)	NULL
transcription	NULL
is	NULL
occurring	NULL
through	NULL
IREF-1	NULL
activation	NULL
(	NULL
44	NULL
)	NULL
.	NULL

No	NULL
major	NULL
difference	NULL
was	NULL
detected	NULL
between	NULL
the	NULL
HLA-DR~	NULL
and	NULL
HLA-DR	NULL
*	NULL
cell	NULL
lines	NULL
concerning	NULL
the	NULL
constitutive	NULL
expression	NULL
levels	NULL
of	NULL
IRF-1	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
or	NULL
GBP-1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
transcripts	NULL
.	NULL

The	NULL
main	NULL
difference	NULL
between	NULL
the	NULL
cell	NULL
lines	NULL
is	NULL
the	NULL
kinetics	NULL
of	NULL
IFN-y	NULL
response	NULL
with	NULL
IRF-1	NULL
,	NULL
whose	NULL
transcript	NULL
accumulation	NULL
is	NULL
reduced	NULL
in	NULL
the	NULL
A375	NULL
and	NULL
42/95	NULL
cell	NULL
lines	NULL
after	NULL
a	NULL
48-h	NULL
treatment	NULL
compared	NULL
with	NULL
the	NULL
other	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
general	NULL
signal	NULL
transduction	NULL
mediated	NULL
by	NULL
the	NULL
cytokine	NULL
is	NULL
similar	NULL
in	NULL
both	NULL
HLA-DR~	NULL
and	NULL
HLA-DR	NULL
*	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

Comparable	NULL
basal	NULL
level	NULL
of	NULL
CHTA	NULL
transcription	NULL
initiated	NULL
from	NULL
promoter	NULL
IV	NULL
in	NULL
both	NULL
melanoma	NULL
cell	NULL
lines	NULL
In	NULL
cells	NULL
such	NULL
as	NULL
fibroblasts	NULL
or	NULL
HLA-DR~	NULL
melanoma	NULL
,	NULL
the	NULL
IFN-y-induced	NULL
transcription	NULL
of	NULL
CITA	NULL
is	NULL
mainly	NULL
initiated	NULL
from	NULL
promoter	NULL
IV	NULL
(	NULL
32	NULL
)	NULL
.	NULL

By	NULL
semiquantitative	NULL
RT-PCR	NULL
,	NULL
we	NULL
have	NULL
analyzed	NULL
the	NULL
initiation	NULL
of	NULL
CHTA	NULL
transcripts	NULL
from	NULL
promoter	NULL
IV	NULL
in	NULL
the	NULL
melanoma	NULL
cell	NULL
lines	NULL
,	NULL
compared	NULL
with	NULL
the	NULL
fibroblast	NULL
BUA	NULL
cell	NULL
line	NULL
.	NULL

As	NULL
the	NULL
sequence	NULL
of	NULL
exon	NULL
1	NULL
differs	NULL
depending	NULL
on	NULL
the	NULL
promoter	NULL
used	NULL
,	NULL
we	NULL
chose	NULL
a	NULL
sense	NULL
primer	NULL
specific	NULL
of	NULL
exon	NULL
1	NULL
transcribed	NULL
from	NULL
promoter	NULL
IV	NULL
and	NULL
an	NULL
antisense	NULL
primer	NULL
hybridizing	NULL
to	NULL
the	NULL
exon	NULL
2	NULL
common	NULL
to	NULL
all	NULL
mRNA	NULL
initiated	NULL
from	NULL
the	NULL
different	NULL
CITA	NULL
promoters	NULL
.	NULL

As	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
treatment	NULL
,	NULL
transcription	NULL
initiated	NULL
from	NULL
promoter	NULL
IV	NULL
is	NULL
not	NULL
observed	NULL
in	NULL
the	NULL
melanoma	NULL
and	NULL
in	NULL
the	NULL
fibroblast	NULL
cell	NULL
lines	NULL
.	NULL

However	NULL
,	NULL
with	NULL
the	NULL
HT144	NULL
and	NULL
A375	NULL
cells	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
treatment	NULL
,	NULL
a	NULL
very	NULL
faint	NULL
band	NULL
was	NULL
detected	NULL
when	NULL
the	NULL
film	NULL
was	NULL
overexposed	NULL
.	NULL

This	NULL
barely	NULL
detectable	NULL
band	NULL
did	NULL
not	NULL
reflect	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
obtained	NULL
in	NULL
the	NULL
preceding	NULL
experiment	NULL
,	NULL
and	NULL
these	NULL
data	NULL
suggested	NULL
that	NULL
the	NULL
HLA-DR	NULL
*	NULL
phenotype	NULL
was	NULL
not	NULL
explained	NULL
by	NULL
a	NULL
constitutive	NULL
expression	NULL
from	NULL
promoter	NULL
IV	NULL
of	NULL
CHTA	NULL
.	NULL

These	NULL
results	NULL
were	NULL
confirmed	NULL
by	NULL
luciferase	NULL
gene	NULL
reporter	NULL
assays	NULL
performed	NULL
with	NULL
a	NULL
CITA	NULL
promoter	NULL
IV	NULL
construct	NULL
transfected	NULL
in	NULL
the	NULL
HT144	NULL
,	NULL
A375	NULL
,	NULL
and	NULL
42/95	NULL
melanoma	NULL
and	NULL
the	NULL
fibroblast	NULL
BUA	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

In	NULL
three	NULL
independent	NULL
experiments	NULL
,	NULL
we	NULL
have	NULL
never	NULL
observed	NULL
more	NULL
than	NULL
a	NULL
2-fold	NULL
difference	NULL
in	NULL
the	NULL
constitutive	NULL
luciferase	NULL
amounts	NULL
in	NULL
the	NULL
HLA-DR	NULL
*	NULL
cells	NULL
compared	NULL
with	NULL
the	NULL
HLA-DR	NULL
and	NULL
BUA	NULL
cell	NULL
lines	NULL
.	NULL

Concerning	NULL
IFN-y	NULL
induction	NULL
of	NULL
the	NULL
CHTA	NULL
promoter	NULL
IV	NULL
,	NULL
the	NULL
induction	NULL
was	NULL
slightly	NULL
higher	NULL
in	NULL
the	NULL
BUA	NULL
cell	NULL
line	NULL
(	NULL
10-fold	NULL
)	NULL
,	NULL
compared	NULL
with	NULL
the	NULL
HT144	NULL
,	NULL
A375	NULL
,	NULL
and	NULL
42/95	NULL
cell	NULL
lines	NULL
(	NULL
~8-fold	NULL
)	NULL
.	NULL

In	NULL
the	NULL
HLA-DR~	NULL
M74	NULL
cell	NULL
line	NULL
,	NULL
stimulation	NULL
by	NULL
IFN-y	NULL
was	NULL
ranging	NULL
from	NULL
20-	NULL
to	NULL
40-fold	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
with	NULL
promoter	NULL
IV	NULL
constructs	NULL
,	NULL
which	NULL
is	NULL
in	NULL
good	NULL
agreement	NULL
with	NULL
the	NULL
high	NULL
induction	NULL
of	NULL
CHTA	NULL
transcripts	NULL
from	NULL
promoter	NULL
IV	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

These	NULL
results	NULL
further	NULL
confirm	NULL
the	NULL
absence	NULL
of	NULL
deregulation	NULL
of	NULL
the	NULL
IFN-y	NULL
transduction	NULL
pathway	NULL
in	NULL
the	NULL
HLA-DR	NULL
*	NULL
cell	NULL
lines	NULL
and	NULL
a	NULL
normal	NULL
usage	NULL
of	NULL
CHTA	NULL
promoter	NULL
IV	NULL
in	NULL
all	NULL
these	NULL
cell	NULL
lines	NULL
.	NULL

Constitutive	NULL
transcription	NULL
of	NULL
CHTA	NULL
in	NULL
HT144	NULL
melanoma	NULL
cell	NULL
line	NULL
mainly	NULL
initiates	NULL
from	NULL
promoter	NULL
III	NULL
We	NULL
had	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
lack	NULL
of	NULL
constitutive	NULL
expression	NULL
of	NULL
CHTA	NULL
in	NULL
epithelioid	NULL
cells	NULL
was	NULL
due	NULL
to	NULL
an	NULL
active	NULL
suppression	NULL
phenomenon	NULL
of	NULL
CITA	NULL
promoter	NULL
III	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
the	NULL
suppression	NULL
mechanism	NULL
might	NULL
be	NULL
inactivated	NULL
in	NULL
the	NULL
HLA-DR*	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
that	NULL
the	NULL
constitutive	NULL
transcription	NULL
of	NULL
CIHTA	NULL
might	NULL
be	NULL
initiated	NULL
from	NULL
the	NULL
promoter	NULL
III	NULL
of	NULL
this	NULL
gene	NULL
.	NULL

RACE-PCR	NULL
was	NULL
then	NULL
performed	NULL
with	NULL
an	NULL
antisense	NULL
primer	NULL
hybridizing	NULL
to	NULL
the	NULL
common	NULL
exon	NULL
2	NULL
shared	NULL
by	NULL
all	NULL
CHTA	NULL
mRNA	NULL
,	NULL
and	NULL
the	NULL
product	NULL
was	NULL
further	NULL
amplified	NULL
using	NULL
a	NULL
primer	NULL
specific	NULL
for	NULL
promoter	NULL
TI-initiated	NULL
transcripts	NULL
.	NULL

In	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
,	NULL
a	NULL
band	NULL
was	NULL
amplified	NULL
in	NULL
untreated	NULL
cells	NULL
,	NULL
and	NULL
its	NULL
intensity	NULL
increased	NULL
in	NULL
cells	NULL
treated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
IFN-y	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
band	NULL
presented	NULL
the	NULL
same	NULL
sequence	NULL
that	NULL
was	NULL
previously	NULL
described	NULL
on	NULL
mRNA	NULL
initiated	NULL
from	NULL
promoter	NULL
III	NULL
in	NULL
B	NULL
lymphocytes	NULL
(	NULL
28	NULL
,	NULL
32	NULL
)	NULL
.	NULL

We	NULL
further	NULL
confirmed	NULL
this	NULL
result	NULL
by	NULL
a	NULL
25-amplification	NULL
cycle	NULL
semiquantitative	NULL
RT-PCR	NULL
using	NULL
a	NULL
sense	NULL
primer	NULL
specific	NULL
for	NULL
promoter	NULL
III-initiated	NULL
transcript	NULL
,	NULL
and	NULL
the	NULL
COM	NULL
B	NULL
lymphocyte	NULL
cell	NULL
line	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
a	NULL
high	NULL
level	NULL
of	NULL
CITA	NULL
mRNA	NULL
was	NULL
initiated	NULL
from	NULL
promoter	NULL
III	NULL
in	NULL
COM	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
,	NULL
the	NULL
42/95	NULL
cell	NULL
line	NULL
did	NULL
not	NULL
display	NULL
any	NULL
CZFTA	NULL
transcript	NULL
even	NULL
in	NULL
experiments	NULL
using	NULL
33-cycle	NULL
PCR	NULL
amplification	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
the	NULL
HLA-DR	NULL
*	NULL
HT144	NULL
and	NULL
A375	NULL
cell	NULL
lines	NULL
,	NULL
CHTA	NULL
product	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
cytokine	NULL
.	NULL

In	NULL
the	NULL
M74	NULL
cell	NULL
line	NULL
,	NULL
and	NULL
in	NULL
the	NULL
BUA	NULL
cell	NULL
line	NULL
,	NULL
a	NULL
faint	NULL
band	NULL
was	NULL
detected	NULL
,	NULL
which	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
constitutive	NULL
transcription	NULL
of	NULL
certain	NULL
HLA-D	NULL
transcripts	NULL
that	NULL
was	NULL
observed	NULL
previously	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

After	NULL
IFN-y	NULL
treatment	NULL
,	NULL
all	NULL
cell	NULL
lines	NULL
displayed	NULL
an	NULL
increase	NULL
of	NULL
CHTA	NULL
transcription	NULL
from	NULL
promoter	NULL
III	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
IFN-responsive	NULL
enhancer	NULL
located	NULL
upstream	NULL
of	NULL
promoter	NULL
III	NULL
(	NULL
34	NULL
,	NULL
36	NULL
)	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
CITA	NULL
in	NULL
the	NULL
HLA-DR	NULL
*	NULL
cell	NULL
lines	NULL
is	NULL
due	NULL
to	NULL
an	NULL
abnormal	NULL
transcription	NULL
initiated	NULL
from	NULL
promoter	NULL
III	NULL
that	NULL
was	NULL
described	NULL
to	NULL
be	NULL
mainly	NULL
used	NULL
in	NULL
B	NULL
lymphocytes	NULL
.	NULL

The	NULL
initiation	NULL
from	NULL
promoter	NULL
III	NULL
of	NULL
CHTA	NULL
in	NULL
HT144	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
IFN-y-responsive	NULL
enhancer	NULL
located	NULL
upstream	NULL
promoter	NULL
III	NULL
To	NULL
determine	NULL
whether	NULL
the	NULL
deregulation	NULL
of	NULL
CHTA	NULL
transcription	NULL
was	NULL
due	NULL
to	NULL
a	NULL
trans-acting	NULL
factor	NULL
,	NULL
luciferase	NULL
reporter	NULL
gene	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
different	NULL
promoter	NULL
IIMV/enhancer	NULL
constructs	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

9	NULL
.	NULL

With	NULL
promoter	NULL
III	NULL
constructs	NULL
alone	NULL
(	NULL
either	NULL
545	NULL
bp	NULL
or	NULL
1723	NULL
bp	NULL
long	NULL
)	NULL
,	NULL
the	NULL
difference	NULL
between	NULL
the	NULL
42/95	NULL
and	NULL
HT144	NULL
cell	NULL
lines	NULL
did	NULL
not	NULL
exceed	NULL
1.5-fold	NULL
in	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

However	NULL
,	NULL
constructs	NULL
containing	NULL
the	NULL
enhancer	NULL
were	NULL
driving	NULL
a	NULL
luciferase	NULL
activity	NULL
7-	NULL
to	NULL
9-fold	NULL
higher	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
than	NULL
in	NULL
the	NULL
42/95	NULL
cells	NULL
,	NULL
these	NULL
values	NULL
representing	NULL
an	NULL
average	NULL
of	NULL
five	NULL
independent	NULL
experiments	NULL
.	NULL

Therefore	NULL
,	NULL
our	NULL
data	NULL
show	NULL
that	NULL
the	NULL
1-kb	NULL
enhancer	NULL
,	NULL
previously	NULL
described	NULL
as	NULL
an	NULL
IFN-responsive	NULL
element	NULL
in	NULL
epithelioid	NULL
cell	NULL
lines	NULL
,	NULL
is	NULL
the	NULL
target	NULL
for	NULL
CITA	NULL
constitutive	NULL
expression	NULL
in	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
properties	NULL
of	NULL
the	NULL
enhancer	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
were	NULL
lost	NULL
when	NULL
the	NULL
SV40	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
,	NULL
pGL3-SV40.Enh	NULL
construct	NULL
)	NULL
replaced	NULL
the	NULL
minimal	NULL
promoter	NULL
III	NULL
of	NULL
CIITA	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
binding	NULL
the	NULL
enhancer	NULL
additionally	NULL
requires	NULL
an	NULL
interaction	NULL
with	NULL
the	NULL
CITA	NULL
promoter	NULL
III	NULL
,	NULL
or	NULL
with	NULL
promoter	NULL
III-binding	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
,	NULL
for	NULL
a	NULL
complete	NULL
activity	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
Brn-2	NULL
transcription	NULL
factor	NULL
Brn-2/N-Oct3	NULL
has	NULL
been	NULL
described	NULL
as	NULL
a	NULL
transcription	NULL
factor	NULL
involved	NULL
in	NULL
the	NULL
tumorigenic	NULL
potential	NULL
of	NULL
melanoma	NULL
cells	NULL
(	NULL
46	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
transfection	NULL
of	NULL
its	NULL
encoding	NULL
cDNA	NULL
activates	NULL
the	NULL
transcription	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
genes	NULL
(	NULL
47	NULL
)	NULL
.	NULL

As	NULL
a	NULL
perfect	NULL
consensus	NULL
binding	NULL
site	NULL
sequence	NULL
(	NULL
CATGCAAAATG	NULL
)	NULL
was	NULL
found	NULL
in	NULL
the	NULL
1-kb	NULL
enhancer	NULL
(	NULL
43	NULL
)	NULL
,	NULL
Brn-2	NULL
represented	NULL
a	NULL
good	NULL
candidate	NULL
for	NULL
the	NULL
deregulation	NULL
of	NULL
CHTA	NULL
transcription	NULL
.	NULL

We	NULL
first	NULL
did	NULL
not	NULL
evidence	NULL
any	NULL
major	NULL
difference	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
its	NULL
mRNA	NULL
or	NULL
protein	NULL
content	NULL
when	NULL
comparing	NULL
42/95	NULL
and	NULL
HT144	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
description	NULL
of	NULL
posttranslational	NULL
events	NULL
modulating	NULL
Brn-2	NULL
activity	NULL
(	NULL
48	NULL
)	NULL
led	NULL
us	NULL
to	NULL
assay	NULL
the	NULL
effect	NULL
of	NULL
a	NULL
deletion	NULL
(	NULL
pIIIDEL2.Brn-Del.Luc	NULL
construct	NULL
)	NULL
or	NULL
a	NULL
mutation	NULL
(	NULL
pIIIDEL2.Bra-Mut.Luc	NULL
construct	NULL
)	NULL
in	NULL
the	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
HLA-DRA-Luc	NULL
HLA-DQA-Luc	NULL
HLA-DPA-Luc	NULL
pGL3-Control	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
Ratio	NULL
RLU	NULL
HT144	NULL
/	NULL
RLU	NULL
42,95	NULL
FIGURE	NULL
3	NULL
.	NULL

-	NULL
Activity	NULL
of	NULL
the	NULL
HLA-DRA	NULL
,	NULL
HLA-DQA	NULL
,	NULL
and	NULL
HLA-DPA	NULL
gene	NULL
promoters	NULL
measured	NULL
by	NULL
luciferase	NULL
assays	NULL
in	NULL
the	NULL
HT144	NULL
and	NULL
42/95	NULL
cell	NULL
lines	NULL
.	NULL

After	NULL
correction	NULL
of	NULL
transfection	NULL
efficiency	NULL
with	NULL
B-galactosidase	NULL
,	NULL
the	NULL
data	NULL
were	NULL
expressed	NULL
as	NULL
the	NULL
ratio	NULL
of	NULL
RLUs~	NULL
'	NULL
obtained	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
divided	NULL
by	NULL
the	NULL
RLUs	NULL
~	NULL
'	NULL
obtained	NULL
in	NULL
the	NULL
42/95	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

Brn-2	NULL
palindromic	NULL
site	NULL
created	NULL
in	NULL
the	NULL
plasmid	NULL
.	NULL

As	NULL
seen	NULL
on	NULL
Fig	NULL
.	NULL

11	NULL
,	NULL
however	NULL
,	NULL
even	NULL
though	NULL
the	NULL
mutation	NULL
provoked	NULL
a	NULL
slight	NULL
decrease	NULL
on	NULL
CITA	NULL
promoter	NULL
III	NULL
activity	NULL
in	NULL
both	NULL
42/95	NULL
and	NULL
HT144	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
did	NULL
not	NULL
evidence	NULL
any	NULL
major	NULL
effect	NULL
of	NULL
the	NULL
Brn-2	NULL
binding	NULL
site	NULL
mutations	NULL
neither	NULL
in	NULL
the	NULL
42/95	NULL
nor	NULL
the	NULL
HT144	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
whereas	NULL
the	NULL
500-bp	NULL
minimal	NULL
promoter	NULL
III	NULL
is	NULL
sufficient	NULL
in	NULL
B	NULL
lymphocytes	NULL
for	NULL
constitutive	NULL
expression	NULL
of	NULL
CHTA	NULL
,	NULL
the	NULL
abnormal	NULL
constitutive	NULL
expression	NULL
of	NULL
CITA	NULL
in	NULL
HT144	NULL
requires	NULL
the	NULL
additional	NULL
presence	NULL
of	NULL
the	NULL
1-kb	NULL
enhancer	NULL
element	NULL
located	NULL
upstream	NULL
promoter	NULL
III	NULL
,	NULL
and	NULL
deregulation	NULL
of	NULL
CITA	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
transacting	NULL
factor	NULL
in	NULL
the	NULL
melanoma	NULL
cell	NULL
line	NULL
.	NULL

Discussion	NULL
Our	NULL
data	NULL
demonstrate	NULL
that	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
in	NULL
melanoma	NULL
is	NULL
correlated	NULL
with	NULL
a	NULL
constitutive	NULL
transcription	NULL
of	NULL
CITA	NULL
.	NULL

This	NULL
phenomenon	NULL
was	NULL
observed	NULL
in	NULL
two	NULL
HLA-DR	NULL
*	NULL
cell	NULL
lines	NULL
established	NULL
from	NULL
unrelated	NULL
patients	NULL
,	NULL
thereby	NULL
suggesting	NULL
that	NULL
it	NULL
might	NULL
not	NULL
originate	NULL
from	NULL
a	NULL
random	NULL
mutagenesis	NULL
event	NULL
,	NULL
but	NULL
might	NULL
be	NULL
linked	NULL
to	NULL
the	NULL
neoplasic	NULL
fate	NULL
or	NULL
differentiation	NULL
state	NULL
of	NULL
this	NULL
tumor	NULL
type	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
deregulation	NULL
of	NULL
CITA	NULL
in	NULL
melanoma	NULL
cells	NULL
occurs	NULL
through	NULL
the	NULL
1-kb	NULL
enhancer	NULL
upstream	NULL
of	NULL
promoter	NULL
III	NULL
,	NULL
which	NULL
was	NULL
previously	NULL
described	NULL
as	NULL
an	NULL
IFN-responsive	NULL
sequence	NULL
(	NULL
34	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Our	NULL
study	NULL
has	NULL
evidenced	NULL
that	NULL
the	NULL
basal	NULL
expression	NULL
level	NULL
of	NULL
different	NULL
IFN-responsive	NULL
genes	NULL
(	NULL
MHC	NULL
class	NULL
I	NULL
,	NULL
GBP-1	NULL
,	NULL
or	NULL
IRF-1	NULL
)	NULL
is	NULL
similar	NULL
in	NULL
both	NULL
HLA-DR	NULL
*	NULL
and	NULL
HLA-DR~	NULL
melanoma	NULL
cell	NULL
lines	NULL
(	NULL
Table	NULL
II	NULL
and	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

This	NULL
demonstrates	NULL
that	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
CITA	NULL
transcript	NULL
is	NULL
not	NULL
caused	NULL
by	NULL
a	NULL
general	NULL
deregulation	NULL
of	NULL
the	NULL
IFN	NULL
transduction	NULL
pathway	NULL
.	NULL

However	NULL
,	NULL
A375	NULL
and	NULL
HT144	NULL
cells	NULL
are	NULL
poorly	NULL
inducible	NULL
by	NULL
this	NULL
cytokine	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
HLA-DR-	NULL
HLA-DR+	NULL
azros	NULL
|	NULL
m74	NULL
|	NULL
BUA	NULL
|	NULL
A375	NULL
|	NULL
HT144	NULL
204	NULL
|	NULL
~	NULL
+	NULL
[	NULL
-	NULL
4	NULL
|-	NULL
00+	NULL
[	NULL
+	NULL
-+	NULL
[	NULL
IFNy	NULL
(	NULL
hn	NULL
)	NULL
ClITA	NULL
cuase	NULL
cam	NULL
fan	NULL
con	NULL
cee	NULL
ease	NULL
|	NULL
GAPDH	NULL
FIGURE	NULL
4	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
of	NULL
CHTA	NULL
transcript	NULL
expression	NULL
in	NULL
the	NULL
different	NULL
melanoma	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
the	NULL
BUA	NULL
cell	NULL
line	NULL
through	NULL
a	NULL
33-cycle	NULL
amplification	NULL
procedure	NULL
.	NULL

cDNAs	NULL
were	NULL
prepared	NULL
from	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
treated	NULL
(	NULL
+	NULL
)	NULL
with	NULL
250	NULL
U/ml	NULL
IFN-y	NULL
for	NULL
6	NULL
h.	NULL
The	NULL
amplification	NULL
products	NULL
were	NULL
detected	NULL
on	NULL
ethidium	NULL
bromide-stained	NULL
gels	NULL
.	NULL

To	NULL
assess	NULL
that	NULL
equal	NULL
amounts	NULL
of	NULL
cDNAs	NULL
were	NULL
used	NULL
,	NULL
a	NULL
16-cycle	NULL
amplification	NULL
was	NULL
performed	NULL
on	NULL
the	NULL
cDNAs	NULL
with	NULL
GAPDH-specific	NULL
primers	NULL
,	NULL
and	NULL
the	NULL
Dig-labeled	NULL
amplification	NULL
products	NULL
were	NULL
stained	NULL
with	NULL
CSPD	NULL
.	NULL

103	NULL
HLA-DR-	NULL
HLA-DR+	NULL
42095	NULL
|	NULL
M74	NULL
BUA	NULL
A375	NULL
[	NULL
o	NULL
6	NULL
as	NULL
|	NULL
0	NULL
6	NULL
as	NULL
|	NULL
o	NULL
6	NULL
as	NULL
|0o	NULL
6	NULL
4s	NULL
[	NULL
0	NULL
6	NULL
48	NULL
(	NULL
hn	NULL
)	NULL
IRF-1	NULL
«	NULL
-o	NULL
«	NULL
»	NULL
«	NULL
»	NULL
fames	NULL
«	NULL
s	NULL
|	NULL
«	NULL
--	NULL
«	NULL
o	NULL
«	NULL
--	NULL
]	NULL
as	NULL
cs	NULL
casl	NULL
«	NULL
--	NULL
»	NULL
-I	NULL
cippL	NULL
FIGURE	NULL
5	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
of	NULL
ZRF-	NULL
]	NULL
transcript	NULL
expression	NULL
in	NULL
the	NULL
different	NULL
melanoma	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
the	NULL
BUA	NULL
cell	NULL
line	NULL
.	NULL

cDNA	NULL
quantification	NULL
with	NULL
GAPDH-specific	NULL
primers	NULL
was	NULL
performed	NULL
on	NULL
Dig-labeled	NULL
amplified	NULL
products	NULL
.	NULL

HLA-D	NULL
genes	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
above	NULL
data	NULL
,	NULL
this	NULL
observation	NULL
might	NULL
be	NULL
explained	NULL
by	NULL
a	NULL
quantitative	NULL
effect	NULL
of	NULL
CIITA	NULL
.	NULL

Indeed	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
over	NULL
a	NULL
certain	NULL
threshold	NULL
of	NULL
CITA	NULL
,	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
reached	NULL
a	NULL
plateau	NULL
(	NULL
49	NULL
)	NULL
.	NULL

In	NULL
the	NULL
HT144	NULL
and	NULL
A375	NULL
cell	NULL
lines	NULL
,	NULL
CHTA	NULL
mRNA	NULL
levels	NULL
are	NULL
constitutively	NULL
high	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
and	NULL
allow	NULL
an	NULL
HLA-DR	NULL
expression	NULL
that	NULL
is	NULL
quite	NULL
similar	NULL
to	NULL
that	NULL
obtained	NULL
with	NULL
the	NULL
induced	NULL
BUA	NULL
fibroblast	NULL
cell	NULL
line	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

When	NULL
the	NULL
HLA-DR	NULL
*	NULL
cell	NULL
lines	NULL
are	NULL
induced	NULL
by	NULL
IFN-y	NULL
,	NULL
the	NULL
CHTA	NULL
transcription	NULL
,	NULL
initiated	NULL
from	NULL
both	NULL
promoters	NULL
III	NULL
and	NULL
IV	NULL
(	NULL
Figs	NULL
.	NULL

6	NULL
and	NULL
8	NULL
)	NULL
,	NULL
does	NULL
not	NULL
result	NULL
in	NULL
a	NULL
drastic	NULL
increase	NULL
of	NULL
HLA-D	NULL
transcription	NULL
,	NULL
as	NULL
CIITA	NULL
is	NULL
already	NULL
in	NULL
high	NULL
amounts	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
cytokine	NULL
.	NULL

Two	NULL
results	NULL
are	NULL
interesting	NULL
to	NULL
point	NULL
out	NULL
concerning	NULL
CITA	NULL
transcription	NULL
.	NULL

Even	NULL
though	NULL
luciferase	NULL
expression	NULL
driven	NULL
by	NULL
CITA	NULL
promoter	NULL
IV	NULL
has	NULL
a	NULL
comparable	NULL
basal	NULL
expression	NULL
level	NULL
in	NULL
HLA-DR	NULL
*	NULL
and	NULL
HLA-DR~	NULL
melanoma	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
,	NULL
a	NULL
low	NULL
amount	NULL
of	NULL
promoter	NULL
IV-initiated	NULL
transcripts	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
HLA-DR	NULL
*	NULL
melanoma	NULL
cell	NULL
lines	NULL
by	NULL
RT-PCR	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
enhancer/promoter	NULL
III	NULL
endogeneous	NULL
sequences	NULL
might	NULL
frans-acti-vate	NULL
the	NULL
adjacent	NULL
promoter	NULL
IV	NULL
.	NULL

The	NULL
second	NULL
point	NULL
is	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
enhancer	NULL
of	NULL
CIITA	NULL
did	NULL
not	NULL
function	NULL
when	NULL
associated	NULL
with	NULL
a	NULL
het-erologous	NULL
promoter	NULL
,	NULL
neither	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
concerning	NULL
its	NULL
constitutive	NULL
expression	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
,	NULL
nor	NULL
in	NULL
a	NULL
fibroblast	NULL
cell	NULL
line	NULL
after	NULL
an	NULL
IFN-y	NULL
treatment	NULL
(	NULL
J.	NULL
Vedrenne	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Luciferase	NULL
assays	NULL
reported	NULL
in	NULL
this	NULL
work	NULL
demonstrated	NULL
that	NULL
constitutive	NULL
expression	NULL
of	NULL
CZTA	NULL
transcription	NULL
occurs	NULL
via	NULL
trans-acting	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
binding	NULL
on	NULL
the	NULL
enhancer	NULL
in	NULL
the	NULL
HLA-DR	NULL
*	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

As	NULL
a	NULL
putative	NULL
candidate	NULL
,	NULL
Brn-2	NULL
,	NULL
was	NULL
dismissed	NULL
in	NULL
this	NULL
study	NULL
,	NULL
a	NULL
random	NULL
mutagenesis	NULL
of	NULL
the	NULL
enhancer	NULL
will	NULL
be	NULL
required	NULL
to	NULL
identify	NULL
the	NULL
factor	NULL
activating	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
CITA	NULL
.	NULL

This	NULL
factor	NULL
might	NULL
either	NULL
be	NULL
a	NULL
suppressor	NULL
inactivated	NULL
during	NULL
the	NULL
tumor-igenesis	NULL
of	NULL
the	NULL
melanoma	NULL
cells	NULL
,	NULL
or	NULL
an	NULL
activator	NULL
gaining	NULL
transcriptional	NULL
activity	NULL
or	NULL
binding	NULL
capacities	NULL
to	NULL
the	NULL
CIITA	NULL
enhancer	NULL
.	NULL

As	NULL
this	NULL
factor	NULL
interacts	NULL
with	NULL
the	NULL
enhancer	NULL
,	NULL
our	NULL
data	NULL
show	NULL
that	NULL
it	NULL
is	NULL
different	NULL
from	NULL
the	NULL
suppressor	NULL
binding	NULL
on	NULL
promoter	NULL
III	NULL
of	NULL
CITA	NULL
evidenced	NULL
in	NULL
epithelial	NULL
cells	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
HLA-DR	NULL
~	NULL
M74	NULL
cell	NULL
line	NULL
is	NULL
displaying	NULL
a	NULL
faint	NULL
constitutive	NULL
expression	NULL
of	NULL
certain	NULL
HLA-D	NULL
genes	NULL
and	NULL
a	NULL
weak	NULL
CITA	NULL
promoter	NULL
I-initiated	NULL
transcription	NULL
relative	NULL
to	NULL
the	NULL
HLA-DR	NULL
*	NULL
cell	NULL
lines	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
factor	NULL
interacting	NULL
with	NULL
the	NULL
enhancer	NULL
might	NULL
have	NULL
different	NULL
levels	NULL
of	NULL
expression	NULL
or	NULL
activation	NULL
depending	NULL
on	NULL
the	NULL
melanoma	NULL
cell	NULL
line	NULL
.	NULL

HLA-DR-	NULL
HLA-DR+	NULL
42/95	NULL
|	NULL
M74	NULL
|	NULL
BUA	NULL
|	NULL
A375	NULL
|HT144	NULL
0	NULL
6	NULL
48	NULL
|	NULL
0	NULL
6	NULL
48	NULL
|0	NULL
6	NULL
48	NULL
|	NULL
0	NULL
6	NULL
48	NULL
|	NULL
0	NULL
6	NULL
48	NULL
|	NULL
IFNy	NULL
(	NULL
hr	NULL
)	NULL
-	NULL
_|	NULL
<	NULL
0	NULL
]	NULL
«	NULL
-|	NULL
--	NULL
@	NULL
]	NULL
CIITA	NULL
«	NULL
o	NULL
«	NULL
a	NULL
«	NULL
a	NULL
fee	NULL
cms	NULL
o	NULL
I	NULL
--	NULL
-I	NULL
--	NULL
-	NULL
***	NULL
**	NULL
]	NULL
capo	NULL
FIGURE	NULL
6	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
of	NULL
promoter	NULL
IV-initiated	NULL
CIHTA	NULL
transcripts	NULL
.	NULL

Amplification	NULL
procedures	NULL
(	NULL
27-	NULL
and	NULL
16-cycle	NULL
)	NULL
were	NULL
applied	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
CHTA	NULL
and	NULL
GAPDH	NULL
transcripts	NULL
,	NULL
and	NULL
Dig-labeled	NULL
products	NULL
were	NULL
stained	NULL
with	NULL
CSPD	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
104	NULL
ABNORMAL	NULL
TRANSCRIPTION	NULL
OF	NULL
CIITA	NULL
IN	NULL
MELANOMA	NULL
CELL	NULL
LINES	NULL
14000	NULL
>	NULL
,	NULL
12000	NULL
z	NULL
10000	NULL
H	NULL
g	NULL
so	NULL
©	NULL
e000	NULL
Ma	NULL
``	NULL
5	NULL
4000	NULL
3	NULL
-	NULL
'	NULL
2000	NULL
‘	NULL
}	NULL
o	NULL
BUA	NULL
42195	NULL
HT144	NULL
A375	NULL
HLA-DR-	NULL
HLA-DR+	NULL
FIGURE	NULL
7	NULL
.	NULL

Activity	NULL
of	NULL
the	NULL
promoter	NULL
IV	NULL
of	NULL
CHTA	NULL
measured	NULL
by	NULL
luciferase	NULL
assays	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
(	NULL
@	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
250	NULL
U/ml	NULL
IFN-y	NULL
for	NULL
24	NULL
h	NULL
(	NULL
C	NULL
]	NULL
)	NULL
.	NULL

Transfection	NULL
efficiency	NULL
was	NULL
corrected	NULL
with	NULL
B-galactosidase	NULL
,	NULL
and	NULL
these	NULL
data	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

In	NULL
many	NULL
nonprofessional	NULL
APC	NULL
,	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
HLA-DQ	NULL
is	NULL
weak	NULL
or	NULL
null	NULL
even	NULL
when	NULL
treated	NULL
with	NULL
IFN-y	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

50	NULL
)	NULL
.	NULL

This	NULL
phenomenon	NULL
was	NULL
observed	NULL
as	NULL
well	NULL
with	NULL
the	NULL
HLA-DR	NULL
~	NULL
melanoma	NULL
cell	NULL
lines	NULL
,	NULL
in	NULL
which	NULL
the	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
HLA-DQ	NULL
molecules	NULL
is	NULL
obviously	NULL
explained	NULL
by	NULL
the	NULL
absence	NULL
of	NULL
HLA-DQA	NULL
transcripts	NULL
,	NULL
even	NULL
after	NULL
a	NULL
48-h	NULL
IFN-y	NULL
treatment	NULL
,	NULL
although	NULL
HLA-DQB	NULL
transcript	NULL
is	NULL
induced	NULL
by	NULL
the	NULL
cytokine	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
HLA-DQA	NULL
promoter	NULL
is	NULL
functional	NULL
,	NULL
as	NULL
the	NULL
transfection	NULL
of	NULL
the	NULL
CIITA	NULL
cDNA	NULL
in	NULL
the	NULL
42/95	NULL
cell	NULL
line	NULL
restores	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
HLA-DQ	NULL
molecules	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
an	NULL
exogenous	NULL
HLA-DQA	NULL
promoter	NULL
is	NULL
able	NULL
to	NULL
drive	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
dose-limiting	NULL
repres-sor	NULL
acting	NULL
on	NULL
this	NULL
promoter	NULL
,	NULL
whose	NULL
effect	NULL
would	NULL
be	NULL
bypassed	NULL
in	NULL
the	NULL
luciferase	NULL
assays	NULL
by	NULL
the	NULL
high	NULL
number	NULL
of	NULL
HLA-DQA	NULL
promoter	NULL
sequences	NULL
carried	NULL
by	NULL
the	NULL
plasmid	NULL
constructs	NULL
.	NULL

Indeed	NULL
,	NULL
a	NULL
HLA-DQA-specific	NULL
binding	NULL
factor	NULL
has	NULL
been	NULL
described	NULL
as	NULL
interacting	NULL
with	NULL
the	NULL
Y	NULL
box	NULL
(	NULL
51	NULL
)	NULL
,	NULL
and	NULL
might	NULL
possess	NULL
a	NULL
repressing	NULL
activity	NULL
specific	NULL
for	NULL
the	NULL
HLA-DQA	NULL
promoter	NULL
.	NULL

An	NULL
alternative	NULL
hypothesis	NULL
was	NULL
given	NULL
by	NULL
Otten	NULL
et	NULL
al	NULL
.	NULL

(	NULL
49	NULL
)	NULL
,	NULL
who	NULL
demonstrated	NULL
that	NULL
cell	NULL
surface	NULL
HLA-DQ	NULL
expression	NULL
required	NULL
a	NULL
higher	NULL
dose	NULL
of	NULL
CIITA	NULL
relative	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
HLA-DR	NULL
and	NULL
HLA-DP	NULL
.	NULL

As	NULL
HLA-DR	NULL
*	NULL
cells	NULL
,	NULL
expressing	NULL
CHTA	NULL
constitutively	NULL
,	NULL
also	NULL
express	NULL
HLA-DQ	NULL
,	NULL
it	NULL
could	NULL
be	NULL
proposed	NULL
that	NULL
a	NULL
threshold	NULL
of	NULL
CIITA	NULL
protein	NULL
must	NULL
be	NULL
crossed	NULL
to	NULL
detect	NULL
HLA-DQ	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
this	NULL
hypothesis	NULL
is	NULL
not	NULL
fully	NULL
satisfying	NULL
with	NULL
the	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
the	NULL
M74	NULL
cell	NULL
line	NULL
treated	NULL
with	NULL
IFN-y	NULL
,	NULL
cell	NULL
surface	NULL
HLA-DQ	NULL
expression	NULL
is	NULL
not	NULL
observed	NULL
,	NULL
and	NULL
HLA-DQA	NULL
transcripts	NULL
are	NULL
not	NULL
detected	NULL
.	NULL

However	NULL
,	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
CHTA	NULL
transcripts	NULL
initiated	NULL
from	NULL
promoter	NULL
IV	NULL
is	NULL
even	NULL
higher	NULL
than	NULL
in	NULL
the	NULL
HLA-DR	NULL
*	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

This	NULL
could	NULL
indicate	NULL
that	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
HLA-DQA	NULL
gene	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
promoter	NULL
Il-initiated	NULL
CITA	NULL
transcripts	NULL
that	NULL
are	NULL
in	NULL
low	NULL
amounts	NULL
in	NULL
both	NULL
HLA-DR	NULL
~	NULL
melanoma	NULL
cell	NULL
lines	NULL
treated	NULL
with	NULL
IFN-y	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

With	NULL
CHTA	NULL
transcripts	NULL
initiated	NULL
from	NULL
promoter	NULL
III	NULL
,	NULL
the	NULL
CIITA	NULL
protein	NULL
can	NULL
be	NULL
translated	NULL
from	NULL
two	NULL
different	NULL
ATGs	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
HLA-DR-	NULL
3	NULL
|__HLA-DR+	NULL
|	NULL
m74	NULL
|	NULL
BUA	NULL
|Y	NULL
|	NULL
A375	NULL
|HT144	NULL
0	NULL
6	NULL
4s	NULL
|	NULL
o	NULL
6	NULL
as|	NULL
0	NULL
6	NULL
4s	NULL
|	NULL
0	NULL
|	NULL
0	NULL
6	NULL
48	NULL
|	NULL
0	NULL
6	NULL
48	NULL
|	NULL
IPNy	NULL
(	NULL
hr	NULL
)	NULL
CIITA	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
fem	NULL
cms	NULL
w	NULL
——-I-I-—-	NULL
———I	NULL
GAPDH	NULL
FIGURE	NULL
8	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
of	NULL
promoter	NULL
IMW-initiated	NULL
CITA	NULL
transcripts	NULL
.	NULL

Twenty-five-cycle	NULL
and	NULL
16-cycle	NULL
amplification	NULL
procedures	NULL
were	NULL
applied	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
CITA	NULL
and	NULL
GAPDH	NULL
transcripts	NULL
,	NULL
and	NULL
Dig-labeled	NULL
products	NULL
were	NULL
stained	NULL
with	NULL
CSPD	NULL
.	NULL

[	NULL
_	NULL
Enhancer	NULL
|	NULL
(	NULL
___	NULL
pill	NULL
___	NULL
)	NULL
Exon	NULL
_	NULL
]	NULL
.	NULL

pliIDEL4.CIITA.Luc	NULL
ClITAA783.lue	NULL
i-	NULL
roduc	NULL
%	NULL
pHICIITA.Luc	NULL
pHIDEL2.CIITA.Luc	NULL
``	NULL
``	NULL
%	NULL
mai	NULL
ad	NULL
pilIDEL3.CIITA.Luc	NULL
«	NULL
6266-5198	NULL
pGL2-Basic	NULL
pHDEL4.CIITA.Luc	NULL
CIITA.1783.luc	NULL
plHICHITA.Luc	NULL
Im	NULL
.	NULL

2	NULL
1	NULL
]	NULL
10	NULL
20	NULL
3	NULL
40	NULL
§	NULL
0	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
Ratio	NULL
RLU	NULL
HT144	NULL
/	NULL
RLU	NULL
42/95	NULL
FIGURE	NULL
9	NULL
.	NULL

Luciferase	NULL
assays	NULL
with	NULL
different	NULL
combinations	NULL
of	NULL
the	NULL
promoter	NULL
III	NULL
and	NULL
enhancer	NULL
sequences	NULL
of	NULL
CITA	NULL
.	NULL

After	NULL
correction	NULL
of	NULL
transfection	NULL
efficiency	NULL
with	NULL
B-galactosidase	NULL
,	NULL
the	NULL
data	NULL
were	NULL
expressed	NULL
as	NULL
the	NULL
ratio	NULL
of	NULL
RLUs_	NULL
'	NULL
obtained	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
divided	NULL
by	NULL
the	NULL
~	NULL
'	NULL
obtained	NULL
in	NULL
the	NULL
42/95	NULL
cells	NULL
.	NULL

These	NULL
experiments	NULL
correspond	NULL
to	NULL
an	NULL
average	NULL
of	NULL
at	NULL
least	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

is	NULL
possible	NULL
that	NULL
the	NULL
longer	NULL
form	NULL
of	NULL
CIITA	NULL
(	NULL
initiated	NULL
from	NULL
the	NULL
first	NULL
ATG	NULL
)	NULL
alone	NULL
might	NULL
be	NULL
able	NULL
of	NULL
trans-activating	NULL
the	NULL
HLA-DQA	NULL
gene	NULL
.	NULL

It	NULL
might	NULL
be	NULL
more	NULL
active	NULL
than	NULL
the	NULL
shorter	NULL
form	NULL
of	NULL
CHITA	NULL
or	NULL
be	NULL
more	NULL
efficient	NULL
concerning	NULL
the	NULL
removal	NULL
of	NULL
an	NULL
HLA-DQA-specific	NULL
repres-sor	NULL
.	NULL

Indeed	NULL
,	NULL
we	NULL
have	NULL
observed	NULL
a	NULL
longer	NULL
form	NULL
of	NULL
the	NULL
CIITA	NULL
protein	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
compared	NULL
with	NULL
the	NULL
42/95	NULL
cell	NULL
line	NULL
(	NULL
G.	NULL
Barbieri	NULL
,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

The	NULL
last	NULL
point	NULL
we	NULL
address	NULL
in	NULL
this	NULL
work	NULL
is	NULL
the	NULL
role	NULL
of	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
in	NULL
melanoma	NULL
,	NULL
as	NULL
this	NULL
expression	NULL
is	NULL
considered	NULL
as	NULL
a	NULL
progression	NULL
marker	NULL
(	NULL
15-17	NULL
)	NULL
.	NULL

Tumor	NULL
Ags	NULL
can	NULL
be	NULL
presented	NULL
via	NULL
the	NULL
HLA-DR	NULL
molecules	NULL
in	NULL
melanoma	NULL
cell	NULL
lines	NULL
(	NULL
8	NULL
)	NULL
,	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
costimulatory	NULL
molecules	NULL
might	NULL
lead	NULL
to	NULL
tumor-specific	NULL
T	NULL
lymphocyte	NULL
anergy	NULL
.	NULL

A	NULL
second	NULL
hypothesis	NULL
is	NULL
that	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
CIITA	NULL
might	NULL
enhance	NULL
cell	NULL
growth	NULL
.	NULL

However	NULL
,	NULL
in	NULL
our	NULL
hands	NULL
,	NULL
CIITA	NULL
overexpression	NULL
in	NULL
transfected	NULL
cells	NULL
tends	NULL
to	NULL
slow	NULL
down	NULL
the	NULL
cell	NULL
growth	NULL
(	NULL
our	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

We	NULL
alternatively	NULL
propose	NULL
that	NULL
the	NULL
factor	NULL
deregulating	NULL
CITA	NULL
transcription	NULL
might	NULL
confer	NULL
a	NULL
selective	NULL
advantage	NULL
to	NULL
the	NULL
tumor	NULL
cells	NULL
.	NULL

Finally	NULL
,	NULL
CIITA	NULL
might	NULL
activate	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
that	NULL
could	NULL
facilitate	NULL
tumor	NULL
invasiveness	NULL
or	NULL
immune	NULL
escape	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
this	NULL
hypothesis	NULL
,	NULL
CIITA	NULL
was	NULL
recently	NULL
shown	NULL
as	NULL
able	NULL
to	NULL
repress	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
ligand	NULL
in	NULL
T	NULL
lymphocytes	NULL
(	NULL
52	NULL
)	NULL
.	NULL

A	NULL
closer	NULL
analysis	NULL
pGL2-basic	NULL
|f	NULL
pllIDEL4.CIITA	NULL
plIDEL2.CITA	NULL
0	NULL
~	NULL
10000	NULL
20000	NULL
30000	NULL
40000	NULL
50000	NULL
RLU	NULL
Firefly	NULL
/	NULL
gal	NULL
pGL3-basic	NULL
|W	NULL
pGL3-SV40	NULL
pGL3-8¥40.Enh	NULL
60	NULL
20	NULL
40	NULL
RLU	NULL
Firefly	NULL
/	NULL
RLU	NULL
Renilla	NULL
plHDEL4.CITA	NULL
Enh	NULL
plIDEL2.CIITA	NULL
sree	NULL
4085	NULL
.	NULL

545	NULL
+123	NULL
FIGURE	NULL
10	NULL
.	NULL

Luciferase	NULL
assays	NULL
performed	NULL
in	NULL
the	NULL
HT144	NULL
cell	NULL
line	NULL
using	NULL
different	NULL
constructs	NULL
whose	NULL
structure	NULL
is	NULL
detailed	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
figure	NULL
.	NULL

The	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
,	NULL
using	NULL
either	NULL
a	NULL
B-galactosidase	NULL
(	NULL
upper	NULL
figure	NULL
)	NULL
or	NULL
a	NULL
Renilla	NULL
(	NULL
lower	NULL
figure	NULL
)	NULL
reporter	NULL
gene	NULL
vector	NULL
to	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

pGL3-5v40	NULL
pGL3-5¥40.Enh	NULL
5266	NULL
.	NULL

-do8s	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
pHIDEL4.CHTA.Luc	NULL
pHIDEL2.CHTA.Luc	NULL
pIIIDEL2.Brn-Del.Luc	NULL
pIIIDEL2.Brn-Mut.Luc	NULL
42/95	NULL
pHIDEL4.CHTA.Luc	NULL
pHIDEL2.CHTA.Luc	NULL
pHIDEL2.Brn-Del.Luc	NULL
pHIDEL2.Brn-Mut.Luc	NULL
HT144	NULL
30000	NULL
0	NULL
10000	NULL
20000	NULL
Luciferase	NULL
activity	NULL
FIGURE	NULL
11	NULL
.	NULL

Luciferase	NULL
assays	NULL
performed	NULL
in	NULL
the	NULL
42/95	NULL
and	NULL
HT144	NULL
melanoma	NULL
cell	NULL
lines	NULL
with	NULL
constructs	NULL
containing	NULL
either	NULL
point	NULL
mutations	NULL
or	NULL
partial	NULL
deletion	NULL
of	NULL
the	NULL
putative	NULL
binding	NULL
site	NULL
of	NULL
Brn-2	NULL
located	NULL
in	NULL
the	NULL
enhancer	NULL
of	NULL
CIITA	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
and	NULL
were	NULL
expressed	NULL
in	NULL
RLUs_	NULL
'	NULL
after	NULL
correction	NULL
for	NULL
transfection	NULL
efficiency	NULL
with	NULL
B-galactosidase	NULL
.	NULL

of	NULL
genes	NULL
activated	NULL
or	NULL
repressed	NULL
by	NULL
CIITA	NULL
must	NULL
therefore	NULL
be	NULL
un-dertaken	NULL
,	NULL
as	NULL
this	NULL
protein	NULL
might	NULL
well	NULL
interact	NULL
with	NULL
a	NULL
much	NULL
broader	NULL
number	NULL
of	NULL
target	NULL
genes	NULL
than	NULL
previously	NULL
thought	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
different	NULL
tumor	NULL
cell	NULL
lines	NULL
display	NULL
MHC	NULL
class	NULL
II	NULL
alteration	NULL
of	NULL
expression	NULL
,	NULL
and	NULL
that	NULL
CIITA	NULL
is	NULL
the	NULL
direct	NULL
or	NULL
indirect	NULL
target	NULL
of	NULL
these	NULL
alterations	NULL
(	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

The	NULL
analysis	NULL
of	NULL
such	NULL
cells	NULL
will	NULL
help	NULL
to	NULL
gain	NULL
further	NULL
insights	NULL
in	NULL
CIITA	NULL
expression	NULL
and	NULL
function	NULL
,	NULL
and	NULL
thereby	NULL
in	NULL
MHC	NULL
class	NULL
II	NULL
gene	NULL
regulation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
studies	NULL
might	NULL
help	NULL
in	NULL
the	NULL
understanding	NULL
of	NULL
the	NULL
mechanisms	NULL
involved	NULL
in	NULL
the	NULL
escape	NULL
of	NULL
tumors	NULL
from	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
E.	NULL
Tartour	NULL
for	NULL
the	NULL
melanoma	NULL
cell	NULL
lines	NULL
,	NULL
E.	NULL
Benveniste	NULL
for	NULL
the	NULL
CIITA	NULL
promoter	NULL
IV	NULL
constructs	NULL
,	NULL
and	NULL
B.	NULL
Grospierre-Lisowska	NULL
and	NULL
R.	NULL
Al-Daccak	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Kirkwood	NULL
,	NULL
J.	NULL
M.	NULL
1996	NULL
.	NULL

Biological	NULL
therapy	NULL
of	NULL
melanoma	NULL
.	NULL

Proc	NULL
.	NULL

Am	NULL
.	NULL

Assoc	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

37:643	NULL
.	NULL

2	NULL
.	NULL

Boon	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
L.	NULL
J	NULL
.	NULL

Old	NULL
.	NULL

1997	NULL
.	NULL

Cancer	NULL
tumor	NULL
antigens	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

9:681	NULL
.	NULL

3	NULL
.	NULL

Rosenberg	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
J.	NULL
C.	NULL
Yang	NULL
,	NULL
D.	NULL
J.	NULL
Schwartzentruber	NULL
,	NULL
P.	NULL
Hwu	NULL
,	NULL
F.	NULL
M.	NULL
Marincola	NULL
,	NULL
S.	NULL
L.	NULL
Topalian	NULL
,	NULL
N.	NULL
P.	NULL
Restifo	NULL
,	NULL
M.	NULL
E.	NULL
Dudley	NULL
,	NULL
S.	NULL
L.	NULL
Schwarz	NULL
,	NULL
P.	NULL
J.	NULL
Spiess	NULL
,	NULL
ct	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

Immunologic	NULL
and	NULL
therapeutic	NULL
evaluation	NULL
of	NULL
a	NULL
synthetic	NULL
peptide	NULL
vaccine	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
patients	NULL
with	NULL
metastatic	NULL
melanoma	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

4:321	NULL
.	NULL

4	NULL
.	NULL

Thurner	NULL
,	NULL
B.	NULL
,	NULL
I.	NULL
Haendle	NULL
,	NULL
C.	NULL
Roder	NULL
,	NULL
D.	NULL
Dieckmann	NULL
,	NULL
P.	NULL
Keikavoussi	NULL
,	NULL
H.	NULL
Jonuleit	NULL
,	NULL
A.	NULL
Bender	NULL
,	NULL
C.	NULL
Maczek	NULL
,	NULL
D.	NULL
Schreiner	NULL
,	NULL
P.	NULL
von	NULL
den	NULL
Driesch	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1999	NULL
.	NULL

Vaccination	NULL
with	NULL
MAGE-3A1	NULL
peptide-pulsed	NULL
mature	NULL
,	NULL
monocyte-derived	NULL
dendritic	NULL
cells	NULL
expands	NULL
specific	NULL
cytotoxic	NULL
T	NULL
cells	NULL
and	NULL
induces	NULL
regression	NULL
of	NULL
some	NULL
metastases	NULL
in	NULL
advanced	NULL
stage	NULL
IV	NULL
melanoma	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

190:1669	NULL
.	NULL

5	NULL
.	NULL

Benitez	NULL
,	NULL
R.	NULL
,	NULL
D.	NULL
Godelaine	NULL
,	NULL
M.	NULL
A.	NULL
Lopez-Nevot	NULL
,	NULL
F.	NULL
Brasseur	NULL
,	NULL
P.	NULL
Jimenez	NULL
,	NULL
M.	NULL
Marchand	NULL
,	NULL
M.	NULL
R.	NULL
Oliva	NULL
,	NULL
N.	NULL
van	NULL
Baren	NULL
,	NULL
T.	NULL
Cabrera	NULL
,	NULL
G.	NULL
Andry	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
B	NULL
,	NULL
-microglobulin	NULL
gene	NULL
result	NULL
in	NULL
a	NULL
lack	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
on	NULL
melanoma	NULL
cells	NULL
of	NULL
two	NULL
patients	NULL
immunized	NULL
with	NULL
MAGE	NULL
peptides	NULL
.	NULL

Tissue	NULL
Antigens	NULL
52:520	NULL
.	NULL

6	NULL
.	NULL

Toes	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
,	NULL
F.	NULL
Ossendorp	NULL
,	NULL
R.	NULL
Offringa	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
.	NULL

1999	NULL
.	NULL

CD4	NULL
T	NULL
cells	NULL
and	NULL
their	NULL
role	NULL
in	NULL
antitumor	NULL
immune	NULL
response	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

189:753	NULL
.	NULL

7	NULL
.	NULL

Topalian	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
M.	NULL
I.	NULL
Gonzales	NULL
,	NULL
M.	NULL
Parkhurst	NULL
,	NULL
Y.	NULL
F.	NULL
Li	NULL
,	NULL
S.	NULL
Southwood	NULL
,	NULL
A.	NULL
Sette	NULL
,	NULL
S.	NULL
A.	NULL
Rosenberg	NULL
,	NULL
and	NULL
P.	NULL
F.	NULL
Robbins	NULL
.	NULL

1996	NULL
.	NULL

Melanoma-specific	NULL
CD4*	NULL
T	NULL
cells	NULL
recognize	NULL
nonmutated	NULL
HLA-DR-restricted	NULL
tyrosinase	NULL
epitopes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183	NULL
;	NULL
1965	NULL
.	NULL

8	NULL
.	NULL

Manici	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Sturniolo	NULL
,	NULL
M.	NULL
A.	NULL
Imro	NULL
,	NULL
J	NULL
.	NULL

Hammer	NULL
,	NULL
F.	NULL
Sinigaglia	NULL
,	NULL
C.	NULL
Noppen	NULL
,	NULL
G.	NULL
Spagnoli	NULL
,	NULL
B.	NULL
Mazzi	NULL
,	NULL
M.	NULL
Bellone	NULL
,	NULL
P.	NULL
Dellabona	NULL
,	NULL
and	NULL
M.	NULL
P.	NULL
Protti	NULL
.	NULL

1999	NULL
.	NULL

Melanoma	NULL
cells	NULL
present	NULL
a	NULL
MAGE-3	NULL
epitope	NULL
to	NULL
CD4	NULL
*	NULL
cytotoxic	NULL
T	NULL
cells	NULL
in	NULL
association	NULL
with	NULL
histocompatibility	NULL
leukocyte	NULL
antigen	NULL
DR11	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

189:871	NULL
.	NULL

9	NULL
.	NULL

Maccalli	NULL
,	NULL
C.	NULL
,	NULL
R.	NULL
Mortarini	NULL
,	NULL
G.	NULL
Parmiani	NULL
,	NULL
and	NULL
A.	NULL
Anichini	NULL
.	NULL

1994	NULL
.	NULL

Multiple	NULL
subsets	NULL
of	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
cytotoxic	NULL
T-cell	NULL
clones	NULL
directed	NULL
to	NULL
autologous	NULL
human	NULL
melanoma	NULL
identified	NULL
by	NULL
cytokine	NULL
profiles	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
57:56	NULL
.	NULL

10	NULL
.	NULL

Becker	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
T.	NULL
Brabletz	NULL
,	NULL
C.	NULL
Czemmy	NULL
,	NULL
C.	NULL
Termeer	NULL
,	NULL
and	NULL
E.	NULL
B.	NULL
Brocker	NULL
.	NULL

1993	NULL
.	NULL

Tumor	NULL
escape	NULL
mechanisms	NULL
from	NULL
immunosurveillance	NULL
:	NULL
induction	NULL
of	NULL
unresponsive-ness	NULL
in	NULL
a	NULL
specific	NULL
MHC-restricted	NULL
CD4	NULL
*	NULL
human	NULL
T	NULL
cell	NULL
clone	NULL
by	NULL
the	NULL
autologous	NULL
MHC	NULL
class	NULL
II*	NULL
melanoma	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

5:1501	NULL
.	NULL

11	NULL
.	NULL

Winchester	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
C.	NULL
Y.	NULL
Wang	NULL
,	NULL
A.	NULL
Gibofsky	NULL
,	NULL
H.	NULL
G.	NULL
Kunkel	NULL
,	NULL
K.	NULL
O.	NULL
Lloyd	NULL
,	NULL
and	NULL
L.	NULL
J	NULL
.	NULL

Old	NULL
.	NULL

1978	NULL
.	NULL

Expression	NULL
of	NULL
Ta-like	NULL
antigens	NULL
on	NULL
cultured	NULL
human	NULL
malignant	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
75:6235	NULL
.	NULL

12	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

105	NULL
Ruiter	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
W.	NULL
Bergman	NULL
,	NULL
K.	NULL
Welvaart	NULL
,	NULL
E.	NULL
Scheffer	NULL
,	NULL
W.	NULL
A.	NULL
van	NULL
Vloten	NULL
,	NULL
C.	NULL
Russo	NULL
,	NULL
and	NULL
S.	NULL
Ferrone	NULL
.	NULL

1984	NULL
.	NULL

Immunchistochemical	NULL
analysis	NULL
of	NULL
malignant	NULL
melanomas	NULL
and	NULL
nevocellular	NULL
nevi	NULL
with	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
distinct	NULL
monomorphic	NULL
determinants	NULL
of	NULL
HLA	NULL
antigens	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

44:3930.	NULL
.	NULL

Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
Kara	NULL
.	NULL

1992	NULL
.	NULL

Sequences	NULL
and	NULL
factors	NULL
:	NULL
a	NULL
guide	NULL
to	NULL
MHC	NULL
class	NULL
II	NULL
transcription	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10:13	NULL
.	NULL

Zeng	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
E.	NULL
Touloukian	NULL
,	NULL
X.	NULL
Wang	NULL
,	NULL
N.	NULL
P.	NULL
Restifo	NULL
,	NULL
S.	NULL
A.	NULL
Rosenberg	NULL
,	NULL
and	NULL
R.	NULL
F.	NULL
Wang	NULL
.	NULL

2000	NULL
.	NULL

Identification	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
epitopes	NULL
from	NULL
NY-ESO-1	NULL
presented	NULL
by	NULL
HLA-DR	NULL
molecules	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

165:1153	NULL
.	NULL

Brocker	NULL
,	NULL
E.	NULL
B.	NULL
,	NULL
L.	NULL
Suter	NULL
,	NULL
and	NULL
C.	NULL
Sorg	NULL
.	NULL

1984	NULL
.	NULL

HLA-DR	NULL
antigen	NULL
expression	NULL
in	NULL
primary	NULL
melanomas	NULL
of	NULL
the	NULL
skin	NULL
.	NULL

J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

82:244.	NULL
.	NULL

Ostmeier	NULL
,	NULL
H.	NULL
,	NULL
B.	NULL
Fuchs	NULL
,	NULL
F.	NULL
Otto	NULL
,	NULL
R.	NULL
Mawick	NULL
,	NULL
A.	NULL
Lippold	NULL
,	NULL
V.	NULL
Krieg	NULL
,	NULL
and	NULL
L.	NULL
Suter	NULL
.	NULL

1999	NULL
.	NULL

Can	NULL
immunohistochemical	NULL
markers	NULL
and	NULL
mitotic	NULL
rate	NULL
improve	NULL
prognostic	NULL
precision	NULL
in	NULL
patients	NULL
with	NULL
primary	NULL
melanoma	NULL
?	NULL

Cancer	NULL
85:2391	NULL
.	NULL

Bambhill	NULL
,	NULL
R.	NULL
L.	NULL
1993	NULL
.	NULL

Pathology	NULL
and	NULL
prognostic	NULL
factors	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Oncol	NULL
.	NULL

5:364	NULL
.	NULL

Staveley-O'Connor	NULL
,	NULL
K.	NULL
,	NULL
E.	NULL
Sotomayor	NULL
,	NULL
J.	NULL
Montgomery	NULL
,	NULL
I.	NULL
Borrello	NULL
,	NULL
L.	NULL
Hwang	NULL
,	NULL
S.	NULL
Fein	NULL
,	NULL
D.	NULL
Pardoll	NULL
,	NULL
and	NULL
H.	NULL
Levitsky	NULL
.	NULL

1998	NULL
.	NULL

Induction	NULL
of	NULL
antigen-specific	NULL
T	NULL
cell	NULL
anergy	NULL
:	NULL
an	NULL
carly	NULL
event	NULL
in	NULL
the	NULL
course	NULL
of	NULL
tumor	NULL
progression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95:1178	NULL
.	NULL

Tsujisaki	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Igarashi	NULL
,	NULL
K.	NULL
Sakaguchi	NULL
,	NULL
M.	NULL
Hisinger	NULL
,	NULL
M.	NULL
Herlyn	NULL
,	NULL
and	NULL
S.	NULL
Ferronc	NULL
.	NULL

1987	NULL
.	NULL

Immunochemical	NULL
and	NULL
functional	NULL
analysis	NULL
of	NULL
HLA	NULL
class	NULL
II	NULL
antigens	NULL
induced	NULL
by	NULL
recombinant	NULL
interferon	NULL
on	NULL
normal	NULL
epidermal	NULL
melanocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

138	NULL
:	NULL
1310	NULL
.	NULL

Klein	NULL
,	NULL
C.	NULL
,	NULL
B.	NULL
Lisowska-Grospierre	NULL
,	NULL
F.	NULL
LeDeist	NULL
,	NULL
A.	NULL
Fischer	NULL
,	NULL
and	NULL
C.	NULL
Griscelli	NULL
.	NULL

1993	NULL
.	NULL

Major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
deficiency	NULL
:	NULL
clinical	NULL
manifestations	NULL
,	NULL
immunologic	NULL
features	NULL
,	NULL
and	NULL
outcome	NULL
.	NULL

J.	NULL
Pediatr	NULL
.	NULL

123:921	NULL
.	NULL

Botazzo	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
I.	NULL
Todd	NULL
,	NULL
R.	NULL
Mirakian	NULL
,	NULL
A.	NULL
Belfiore	NULL
,	NULL
and	NULL
R.	NULL
Pujol-Borrell	NULL
.	NULL

1986	NULL
.	NULL

Organ-specific	NULL
autoimmunity	NULL
:	NULL
a	NULL
(	NULL
1986	NULL
)	NULL
overview	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

94:137	NULL
.	NULL

Ting	NULL
,	NULL
J	NULL
.	NULL

P.-Y	NULL
.	NULL

,	NULL
and	NULL
X.-S.	NULL
Zhu	NULL
.	NULL

1999	NULL
.	NULL

Class	NULL
II	NULL
MHC	NULL
genes	NULL
:	NULL
a	NULL
model	NULL
gene	NULL
regulatory	NULL
system	NULL
with	NULL
great	NULL
biologic	NULL
consequences	NULL
.	NULL

Microbes	NULL
Infect	NULL
.	NULL

1:855	NULL
.	NULL

Masternak	NULL
,	NULL
K.	NULL
,	NULL
E.	NULL
Barras	NULL
,	NULL
M.	NULL
Zufferey	NULL
,	NULL
B.	NULL
Conrad	NULL
,	NULL
G.	NULL
Corthals	NULL
,	NULL
R.	NULL
Aebersold	NULL
,	NULL
J.	NULL
C.	NULL
Sanchez	NULL
,	NULL
D.	NULL
F.	NULL
Hochstrasser	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1998	NULL
.	NULL

A	NULL
gene	NULL
encoding	NULL
a	NULL
novel	NULL
RFX-associated	NULL
transactivator	NULL
is	NULL
mutated	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
patients	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

20:273	NULL
.	NULL

Durand	NULL
,	NULL
B.	NULL
,	NULL
P.	NULL
Sperisen	NULL
,	NULL
P.	NULL
Emery	NULL
,	NULL
B.	NULL
Barras	NULL
,	NULL
M.	NULL
Zufferey	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1997	NULL
.	NULL

RFXAP	NULL
,	NULL
a	NULL
novel	NULL
subunit	NULL
of	NULL
the	NULL
RFX	NULL
DNA	NULL
binding	NULL
complex	NULL
,	NULL
is	NULL
mutated	NULL
in	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:1045	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
E.	NULL
Barras	NULL
,	NULL
M.	NULL
Zufferey	NULL
,	NULL
M.	NULL
R.	NULL
Hadam	NULL
,	NULL
B.	NULL
Mach	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
novel	NULL
DNA-binding	NULL
regulatory	NULL
factor	NULL
is	NULL
mutated	NULL
in	NULL
primary	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
(	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:1021	NULL
.	NULL

Moreno	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
G.	NULL
W.	NULL
Beresford	NULL
,	NULL
P.	NULL
Louis-Plence	NULL
,	NULL
A.	NULL
C.	NULL
Morris	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Boss	NULL
.	NULL

1999	NULL
.	NULL

CREB	NULL
regulates	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
a	NULL
CITA-dependent	NULL
manner	NULL
.	NULL

Immunity	NULL
10:143	NULL
.	NULL

Mantovani	NULL
,	NULL
R.	NULL
,	NULL
U.	NULL
Pessara	NULL
,	NULL
F.	NULL
Tronche	NULL
,	NULL
X.-Y	NULL
.	NULL

Li	NULL
,	NULL
A.-M.	NULL
Knapp	NULL
,	NULL
J.-L.	NULL
Pasquali	NULL
,	NULL
C.	NULL
Benoist	NULL
,	NULL
and	NULL
D.	NULL
Mathis	NULL
.	NULL

1992	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
to	NULL
NF-Y	NULL
define	NULL
its	NULL
function	NULL
in	NULL
MHC	NULL
class	NULL
II	NULL
and	NULL
albumin	NULL
gene	NULL
transcription	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:3315	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
L.	NULL
A.	NULL
Otten	NULL
,	NULL
M.	NULL
Zufferey	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1993	NULL
.	NULL

Complementation	NULL
cloning	NULL
of	NULL
an	NULL
MHC	NULL
class	NULL
II	NULL
transactivator	NULL
mutated	NULL
in	NULL
hereditary	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
(	NULL
or	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
)	NULL
.	NULL

Cell	NULL
75:135	NULL
.	NULL

Zhu	NULL
,	NULL
X.	NULL
S.	NULL
,	NULL
M.	NULL
W.	NULL
Linhoff	NULL
,	NULL
G.	NULL
Li	NULL
,	NULL
K.	NULL
C.	NULL
Chin	NULL
,	NULL
S.	NULL
N.	NULL
Maity	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Ting	NULL
.	NULL

2000	NULL
.	NULL

Transcriptional	NULL
scaffold	NULL
:	NULL
CIITA	NULL
interacts	NULL
with	NULL
NF-Y	NULL
,	NULL
RFX	NULL
,	NULL
and	NULL
CREB	NULL
to	NULL
cause	NULL
stereospecific	NULL
regulation	NULL
of	NULL
the	NULL
class	NULL
II	NULL
major	NULL
histocompatibility	NULL
complex	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

20:6051	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
C.	NULL
A.	NULL
Siegrist	NULL
,	NULL
A.	NULL
Mottet	NULL
,	NULL
B.	NULL
Lisowska-Grospierre	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1994	NULL
.	NULL

Regulation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
by	NULL
interferon-y	NULL
mediated	NULL
by	NULL
the	NULL
transactivator	NULL
gene	NULL
CIITA	NULL
.	NULL

Science	NULL
265:106	NULL
.	NULL

Silacci	NULL
,	NULL
P.	NULL
,	NULL
A.	NULL
Mottet	NULL
,	NULL
V.	NULL
Steimle	NULL
,	NULL
W.	NULL
Reith	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1994	NULL
.	NULL

Developmental	NULL
extinction	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
gene	NULL
expression	NULL
in	NULL
plasmocytes	NULL
is	NULL
mediated	NULL
by	NULL
silencing	NULL
of	NULL
the	NULL
transactivator	NULL
gene	NULL
CIITA	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1329	NULL
.	NULL

Mublethaler-Mottet	NULL
,	NULL
A.	NULL
,	NULL
L.	NULL
A.	NULL
Otten	NULL
,	NULL
V.	NULL
Steimle	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1997	NULL
.	NULL

Expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
in	NULL
different	NULL
cellular	NULL
and	NULL
functional	NULL
compartments	NULL
is	NULL
controlled	NULL
by	NULL
differential	NULL
usage	NULL
of	NULL
multiple	NULL
promoters	NULL
of	NULL
the	NULL
transactivator	NULL
CIITA	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:2851	NULL
.	NULL

Lennon	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
C.	NULL
Ottone	NULL
,	NULL
G.	NULL
Rigaud	NULL
,	NULL
L.	NULL
L.	NULL
Deaven	NULL
,	NULL
J.	NULL
Longmire	NULL
,	NULL
M.	NULL
Fellous	NULL
,	NULL
R.	NULL
Bono	NULL
,	NULL
and	NULL
C.	NULL
Alcaide-Loridan	NULL
.	NULL

1997	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
B-cell-specific	NULL
promoter	NULL
for	NULL
the	NULL
human	NULL
class	NULL
II	NULL
transactivator	NULL
.	NULL

Immunogenetics	NULL
45:266	NULL
.	NULL

Piskurich	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Y.	NULL
Wang	NULL
,	NULL
M.	NULL
W.	NULL
Linhoff	NULL
,	NULL
L.	NULL
C.	NULL
White	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Ting	NULL
.	NULL

1998	NULL
.	NULL

Identification	NULL
of	NULL
distinct	NULL
regions	NULL
of	NULL
5°	NULL
flanking	NULL
DNA	NULL
that	NULL
mediate	NULL
constitutive	NULL
,	NULL
IFN-y	NULL
,	NULL
STAT1	NULL
,	NULL
and	NULL
TGP-B-regulated	NULL
expression	NULL
of	NULL
the	NULL
class	NULL
II	NULL
transactivator	NULL
gene	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:233	NULL
.	NULL

Mublethaler-Mottet	NULL
,	NULL
A.	NULL
,	NULL
W.	NULL
Di	NULL
Berardino	NULL
,	NULL
L.	NULL
A.	NULL
Otten	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
transactivator	NULL
CITA	NULL
by	NULL
interferon-y	NULL
requires	NULL
cooperative	NULL
interaction	NULL
between	NULL
Statl	NULL
and	NULL
USB-1	NULL
.	NULL

Immunity	NULL
8:157	NULL
.	NULL

Piskurich	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
M.	NULL
W.	NULL
Linhoff	NULL
,	NULL
Y.	NULL
Wang	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Ting	NULL
.	NULL

1999	NULL
.	NULL

Two	NULL
distinct	NULL
y	NULL
interferon-inducible	NULL
promoters	NULL
of	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
transactivator	NULL
gene	NULL
are	NULL
differentially	NULL
regulated	NULL
by	NULL
STAT1	NULL
,	NULL
interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
,	NULL
and	NULL
transforming	NULL
growth	NULL
factor	NULL
B.	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

19:431	NULL
.	NULL

Bono	NULL
,	NULL
R.	NULL
,	NULL
F.	NULL
Hyafil	NULL
,	NULL
J.	NULL
Kalil	NULL
,	NULL
V.	NULL
Koblar	NULL
,	NULL
J.	NULL
Wiels	NULL
,	NULL
E.	NULL
Wollman	NULL
,	NULL
and	NULL
M.	NULL
Fellous	NULL
.	NULL

1979	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
against	NULL
HLA-DRw	NULL
antigens	NULL
.	NULL

Transplant	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

11:109	NULL
.	NULL

Watson	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
R.	NULL
DeMars	NULL
,	NULL
I.	NULL
S.	NULL
Trowbridge	NULL
,	NULL
and	NULL
F.	NULL
H.	NULL
Bach	NULL
.	NULL

1983	NULL
.	NULL

Detection	NULL
of	NULL
a	NULL
novel	NULL
human	NULL
class	NULL
II	NULL
HLA	NULL
antigen	NULL
.	NULL

Nature	NULL
304:358	NULL
.	NULL

Fermand	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
C.	NULL
Schmitt	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Brouct	NULL
.	NULL

1985	NULL
.	NULL

Distribution	NULL
of	NULL
class	NULL
II	NULL
DQ	NULL
antigens	NULL
on	NULL
normal	NULL
and	NULL
leukemic	NULL
lymphoid	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

15:1183	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
106	NULL
40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

Spacte	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
and	NULL
E.	NULL
S.	NULL
Mocarski	NULL
.	NULL

1985	NULL
.	NULL

Regulation	NULL
of	NULL
cytomegalovirus	NULL
gene	NULL
expression	NULL
:	NULL
&	NULL
and	NULL
promoters	NULL
are	NULL
transactivated	NULL
by	NULL
viral	NULL
functions	NULL
in	NULL
permissive	NULL
human	NULL
fibroblasts	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

56:135	NULL
.	NULL

Peijnenburg	NULL
,	NULL
A.	NULL
,	NULL
R.	NULL
Van	NULL
den	NULL
Berg	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

Van	NULL
Eggermond	NULL
,	NULL
O.	NULL
Sanal	NULL
,	NULL
J.	NULL
M.	NULL
Vossen	NULL
,	NULL
A.	NULL
M.	NULL
Lennon	NULL
,	NULL
C.	NULL
Alcaide-Loridan	NULL
,	NULL
and	NULL
P.	NULL
J	NULL
.	NULL

Van	NULL
den	NULL
Elsen	NULL
.	NULL

2000	NULL
.	NULL

Defective	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
an	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
patient	NULL
is	NULL
caused	NULL
by	NULL
a	NULL
novel	NULL
deletion	NULL
of	NULL
a	NULL
splice	NULL
donor	NULL
site	NULL
in	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
transactivator	NULL
gene	NULL
.	NULL

Immunogenetics	NULL
51:42	NULL
.	NULL

Rohn	NULL
,	NULL
W.	NULL
,	NULL
L.	NULL
P.	NULL
Tang	NULL
,	NULL
Y.	NULL
Dong	NULL
,	NULL
and	NULL
E.	NULL
N.	NULL
Benveniste	NULL
.	NULL

1999	NULL
.	NULL

IL-1	NULL
$	NULL
inhibits	NULL
IFN-y-induced	NULL
class	NULL
II	NULL
MHC	NULL
expression	NULL
by	NULL
suppressing	NULL
transcription	NULL
of	NULL
the	NULL
class	NULL
II	NULL
transactivator	NULL
gene	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:886	NULL
.	NULL

Li	NULL
,	NULL
P.	NULL
,	NULL
X	NULL
.	NULL

He	NULL
,	NULL
M.	NULL
R.	NULL
Gerrero	NULL
,	NULL
M.	NULL
Mok	NULL
,	NULL
A.	NULL
Aggarwal	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
.	NULL

1993	NULL
.	NULL

Spacing	NULL
and	NULL
orientation	NULL
of	NULL
bipartite	NULL
DNA-binding	NULL
motifs	NULL
as	NULL
potential	NULL
functional	NULL
determinants	NULL
for	NULL
POU	NULL
domain	NULL
factors	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:2483.	NULL
.	NULL

Schindler	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
.	NULL

1995	NULL
.	NULL

Transcriptional	NULL
responses	NULL
to	NULL
polypeptide	NULL
ligands	NULL
:	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

64:621	NULL
.	NULL

Lennon	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
C.	NULL
Oftone	NULL
,	NULL
M.	NULL
Rosemblatt	NULL
,	NULL
M.	NULL
Fellous	NULL
,	NULL
M.	NULL
R.	NULL
Bono	NULL
,	NULL
and	NULL
C.	NULL
Alcaide-Loridan	NULL
.	NULL

1998	NULL
.	NULL

CHTA	NULL
B-cell-specific	NULL
promoter	NULL
suppression	NULL
in	NULL
MHC	NULL
class	NULL
I-silenced	NULL
cell	NULL
hybrids	NULL
.	NULL

Immunogenetics	NULL
48:283	NULL
.	NULL

Angus	NULL
,	NULL
J.	NULL
,	NULL
F.	NULL
Thomson	NULL
,	NULL
K.	NULL
Murphy	NULL
,	NULL
E.	NULL
Baker	NULL
,	NULL
G.	NULL
R.	NULL
Sutherland	NULL
,	NULL
P.	NULL
G.	NULL
Parsons	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Sturm	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
Brn-2	NULL
gene	NULL
regulates	NULL
the	NULL
melanocytic	NULL
phenotype	NULL
and	NULL
tumorigenic	NULL
potential	NULL
of	NULL
human	NULL
melanoma	NULL
cells	NULL
.	NULL

Oncogene	NULL
11:691	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

ABNORMAL	NULL
TRANSCRIPTION	NULL
OF	NULL
CIITA	NULL
IN	NULL
MELANOMA	NULL
CELL	NULL
LINES	NULL
Eisen	NULL
,	NULL
T.	NULL
,	NULL
D.	NULL
J.	NULL
Easty	NULL
,	NULL
D.	NULL
C.	NULL
Bennett	NULL
,	NULL
and	NULL
C.	NULL
R.	NULL
Goding	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
POU	NULL
domain	NULL
transcription	NULL
factor	NULL
Brn-2	NULL
:	NULL
elevated	NULL
expression	NULL
in	NULL
malignant	NULL
melanoma	NULL
and	NULL
regulation	NULL
of	NULL
melanocyte-specific	NULL
gene	NULL
expression	NULL
.	NULL

Oncogene	NULL
11:2157	NULL
.	NULL

Eisen	NULL
,	NULL
T.	NULL
G.	NULL
1996	NULL
.	NULL

The	NULL
control	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
melanocytes	NULL
and	NULL
melano-mas	NULL
.	NULL

Melanoma	NULL
Res	NULL
.	NULL

6:277	NULL
.	NULL

Often	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
V.	NULL
Steimle	NULL
,	NULL
S.	NULL
Bontron	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1998	NULL
.	NULL

Quantitative	NULL
control	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
by	NULL
the	NULL
transactivator	NULL
CITA	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28:473	NULL
.	NULL

Alcaide-Loridan	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
M.	NULL
Lennon	NULL
,	NULL
M.	NULL
R.	NULL
Bono	NULL
,	NULL
R.	NULL
Barbouche	NULL
,	NULL
K.	NULL
Dellagi	NULL
,	NULL
andM	NULL
.	NULL

Fellous	NULL
.	NULL

1999	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
isotype	NULL
chains	NULL
.	NULL

Microbes	NULL
Infect	NULL
.	NULL

1:929	NULL
.	NULL

Kimura	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
T.	NULL
Sasazuki	NULL
.	NULL

1991	NULL
.	NULL

Polymorphism	NULL
in	NULL
the	NULL
5	NULL
``	NULL
flanking	NULL
region	NULL
of	NULL
the	NULL
HLA-DQA1	NULL
gene	NULL
and	NULL
its	NULL
relation	NULL
to	NULL
the	NULL
DR-DQ	NULL
phenotype	NULL
.	NULL

In	NULL
HLA	NULL
1997	NULL
,	NULL
Vol	NULL
.	NULL

2	NULL
.	NULL

K.	NULL
Tsui	NULL
,	NULL
M.	NULL
Aizawa	NULL
,	NULL
and	NULL
T.	NULL
Sasazuki	NULL
,	NULL
eds	NULL
.	NULL

Oxford	NULL
Science	NULL
Publications	NULL
,	NULL
Oxford	NULL
,	NULL
p.	NULL
382	NULL
.	NULL

Gourley	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
and	NULL
C.	NULL
H.	NULL
Chang	NULL
.	NULL

2001	NULL
.	NULL

The	NULL
class	NULL
II	NULL
transactivator	NULL
prevents	NULL
activation-induced	NULL
cell	NULL
death	NULL
by	NULL
inhibiting	NULL
fas	NULL
ligand	NULL
gene	NULL
expression	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

166:2917	NULL
.	NULL

Lennon	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
Ottone	NULL
,	NULL
A.	NULL
Peijnenburg	NULL
,	NULL
C.	NULL
Hamon-Benais	NULL
,	NULL
F.	NULL
Colland	NULL
,	NULL
S.	NULL
Gobin	NULL
,	NULL
P.	NULL
van	NULL
den	NULL
Elsen	NULL
,	NULL
M.	NULL
Fellous	NULL
,	NULL
R.	NULL
Bono	NULL
,	NULL
and	NULL
C.	NULL
Alcaide-Loridan	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
RAG	NULL
cell	NULL
line	NULL
defines	NULL
a	NULL
new	NULL
complementation	NULL
group	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
.	NULL

Immunogenetics	NULL
43:352	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
,	NULL
G.	NULL
D.	NULL
Ussery	NULL
,	NULL
M.	NULL
M.	NULL
Muncaster	NULL
,	NULL
B.	NULL
L.	NULL
Gallic	NULL
,	NULL
and	NULL
G.	NULL
Blanck	NULL
.	NULL

1994	NULL
.	NULL

Evidence	NULL
for	NULL
retinoblastoma	NULL
protein	NULL
(	NULL
RB	NULL
)	NULL
dependent	NULL
and	NULL
independent	NULL
IFN-y	NULL
re-sponses	NULL
:	NULL
RB	NULL
coordinately	NULL
rescues	NULL
IFN-y	NULL
induction	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
gene	NULL
transcription	NULL
in	NULL
noninducible	NULL
breast	NULL
carcinoma	NULL
cells	NULL
.	NULL

Oncogene	NULL
9:1015	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

